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     INTRODUCTION 
 
Acute renal failure (ARF) in critically ill patients is associated with a high 
mortality rate. Several pathophysiologic mechanisms associated with ARF have enhanced 
our understanding of the disease. ARF can result from alterations in renal perfusion, 
changes in glomerular filtration and tubular dysfunction. Early intervention and 
correction of these factors can alter the effects of ARF. Several new potential 
interventions including renal replacement therapy (RRT) have been developed that can 
change the course of ARF in the critically ill. Despite improvements in intensive care and 
dialytic technology, there have not been significant improvements in patient survival over 
the past few decades. There is no consensus definition of ARF in critically ill patients. 
Many different definitions have been used in the literature, making comparisons difficult. 
Timely identification of the severity of ARF using relevant criteria and aggressive 
intervention remains the key to higher success rates in dealing with these patients. In our 
study we aim to assess the ability to identify the severity of ARF in the surgical intensive 
care unit using a new criteria called the RIFLE score (Risk, Injury, Failure, Loss and End 
stage renal disease), and the effects of early identification of the vulnerable population on 
the outcome.  
 
 
 
 
 
 
 
 
 
 
 7
  
 
 
 
 
 AIMS AND OBJECTIVES  
 
 
 
• To determine the incidence of Acute Renal Failure in a cohort of patients with 
risk, injury and failure factors admitted to the Surgical Intensive Care Unit of the 
Christian Medical College Hospital. 
 
• To assess the mortality in patients who developed acute renal failure.  
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I.     Introduction  
The clinical condition of Acute Renal Failure (ARF) is said to occur in 1% 
to 25% of critically ill patients depending on the population being studied and the criteria 
used to define its presence 1,2 . Acute Renal failure  characterized by a sudden loss of the 
ability of the kidneys to excrete wastes, concentrate urine, conserve electrolytes, and 
maintain fluid balance, is a frequent clinical phenomenon, particularly in the intensive 
care unit, where it is associated with a mortality of between 50% and 80% 3-6.  
Bywaters and Beall described an acute loss of kidney function that 
occurred in severely injured crush victims during the bombing of London in World War 
II 7.  Acute tubular necrosis (ATN) was the term used to describe this clinical entity. ARF 
as a result of ATN may develop in 10% of all patients admitted to the intensive care unit 
(ICU) and is associated with high morbidity and mortality. Historical sequence of events 
suggests that early intervention could prevent the occurrence of ARF 7. Moreover early 
intervention with fluid resuscitation was shown to prevent the progression from prerenal 
azotemia to established ARF 7 . 
II. Expanded definitions for ARF 
The definitions of acute renal failure have varied enormously from one clinical 
series to another (Table 1). The accuracy of a creatinine clearance measurement is 
limited, because as glomerular filtration rate (GFR) falls creatinine secretion is increased, 
and thus the rise in serum creatinine is less8,9 . Thus creatinine excretion is much greater 
than the filtered load, resulting in a potentially large overestimation of the GFR (as much  
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                                                                Table 1 
                          Historical definitions for ARF 18  Author  Year 
> 1 mg% rise in Scr or 20 mg% or 50% rise in BUN Eisenberg et al  1981 
0.5 mg% rise in Scr if baseline <1.9mg% 
1 mg% rise in Scr if baseline is 2.0 to 4.9 mg% 
1.5 mg% rise in Scr if baseline is >5 mg% 
Hou et al  1983 
50 % rise in Scr to at least  4 mg% Parfrey et al  1989 
Six graded criteria  
>0.3 mg% and 20% rise in Scr on day 1,2,or 3 and day 5,6 or 7 
0.3 mg% rise on day 1,2 ,3 
>20% rise Scr on day 1 or2 
2 mg % rise on day 1 or 2 
1 mg % rise in Scr on day1 
20 mg% or 50%rise in BUN on day 1 
Lautin et al  1991 
Sudden rise in Scr of 2 mg% with prior normal function 
Sudden rise in Scr of >50 % with baseline “mild to moderate” 
CRF with Scr < 3.0 mg% ,Elevation of Scr at admission with 
normal or increased renal size(except with myeloma or 
hydronephrosis ) 
Pascual and 
Liano  
1996 
0.5 mg% rise in Scr to at least 2 mg%, or admission Scr >2 
mg% with no history of renal disease  
Kurnik et al  1998 
> 50% rise in Scr in absence of volume responsive pre renal 
status,> 1 mg% rise in Scr with known renal insufficiency 
Fiaccadori et al  1999 
SCr >3 mg% with baseline <1.8 mg% or acute decrease in 
creatinine clearance of <25% following surgery, trauma, 
hypotension  or sepsis 
Hirschberg et al  1999 
Table 1 contd.  
0.9 mg % rise if baseline Scr <2.0 mg% to at least 2 mg%  
1.5 mg % rise in Scr if baseline Scr > 2.0 mg% 
Behrend and 
Miller  
1999 
0.5 mg % rise in Scr to at least 2.0 mg%or admission Scr >2.0 
mg% with no past history of renal disease  
Obialo et al  2002 
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as a twofold difference)8. However, for clinical purposes it is important to 
determine whether renal function is stable or getting worse or better. This can usually be 
determined by monitoring serum creatinine alone 10.  
The degree to which serum creatinine changes from baseline will reflect 
the change in GFR. Serum creatinine is readily and easily measured and it is specific for 
renal function, while urea (or blood urea nitrogen) is a nonspecific marker of renal 
function, making it a poor marker relative to creatinine. Urine output is far less specific 
except when it is severely decreased or absent. Severe ARF can exist despite normal 
urine output (i.e. non oliguric) but changes in urine output can occur long before 
biochemical changes are apparent.  
The ability to predict hospital mortality in 2 ARF-specific severity-of-
illness scoring methods, the Risk, Injury, Failure, Loss, End-Stage Renal Disease 
(RIFLE) score and the other criteria were compared. Maximum RIFLE score for the first 
3 days in the ICU was found to be an independent predictor of hospital  mortality along 
with admission sequential organ failure assessment (SOFA) score 11.  
III. Incidence of ARF   
Hou et al reported an ARF incidence estimate of 4.9% 12. Shusterman et al  
conducted a similar study identifying ARF in 1.9% of hospitalized patients 13. A follow-
up study recently published by Hou and colleagues 14 showed an increase in incidence to  
7% with a similar spectrum of risk factors. In intensive care units, again a few studies 
have mentioned the incidence of acute renal failure. Clermont et al 4 have described an 
 12
 
Table-2 : Annual incidence of ARF in different clinical studies  
 
 
 
 
 
Study Incidence Study limitations 
Hou et al.12 4.9%  Wide range of creatinine values allowed 
(under inclusion criteria (upto 5 mg%) 
Nash et al 14 7.2% Broad definition for ARF as the above 
Kaufman et al 19 0.9% Broad definition for ARF 
Liaño et al.20 
 
0.37%. The ICD-9-CM (sensitivity of only 19.2%) 
was used for coding. 
Liangos et al 21 1.9%. 
 
The ICD-9-CM again was the coding used 
Chertow et al 1            13% Small elevations in serum creatinine were 
associated with increased mortality risk.  
Schusterman et al 13 1.9% Study was restricted to a single center 
Ballal et al 16 13% No specific limitation 
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incidence of 17% of admissions with ARF in their study of which half had ARF at the 
time of admission and the other half following their admission into ICU.   
Singhri et al in their study in a tertiary care referral center quote an incidence of ARF 
amongst all patients undergoing treatment in their hospital of  5-7% 15. In a tertiary level 
hospital in a developing country like India incidence of ARF in hospitalized patients is 
between 1- 5% and in the ICU is about 10-30% 16 . A prospective study in a tertiary care 
hospital in lucknow, India showed that 17% of cases of ARF were critically ill 17. The 
incidence of ARF in various studies are  given in tables 2 and 3. 
IV.   The Etiology of Acute Renal Failure 
Risk factors 
Drugs : Aminoglycosides are well-recognized nephrotoxins that are often used and the 
incidence of ARF with aminoglycoside therapy ranges from 5 to 25%. The accumulation 
of drug in renal tubular epithelial cells appears to be an important pathophysiologic 
mechanism but alterations in renal plasma flow may also occur. Renal hypoperfusion 
predisposes to aminoglycoside nephrotoxicity. Prins et al  29  found that compared with 
conventional thrice-daily dosing, once-daily amino glycoside dosing resulted in a marked 
reduction in the incidence of ARF (defined as an increase in serum creatinine of 
0.5 mg/dl) from 24% to only 5% .Two recent meta-analyses subsequently demonstrated a 
non significant trend toward less nephrotoxicity  with relative risks of ARF of 0.74 to 
0.87.  Equal clinical and microbiologic efficacy has been consistently demonstrated.  30, 31   
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                  Study   Clinical Circumstance  Incidence 
Hoste et al 22 
Schrier et al 23 
Sepsis 
Moderate sepsis 
Severe sepsis 
Septic shock  
15-30% 
19% 
23% 
51% 
Hoste et al 22 Increasing age  16.2% 
Liano et al 6 Male predominance  65% 
Thakar et al 24 predominance of ARF in females 
after cardiac surgery  
68.5% 
Gul et al  25 Patients with ventilator associated 
pneumonia (VAP)  
38% 
Belbi et al 26 Burns  11% 
Hoste et al 27 Pre ecclampsia  25% 
Frederic S.  
Bongard et al  2 
Immunocompromised  
Seropositive for HIV 
50% 
 
 
 
Table 3 : Incidence of Acute renal failure in special circumstances. 
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The anti fungal agent amphotericin B causes significant renal dysfunction. 
In a randomized trial of liposomal amphotericin B versus conventional amphotericin B in 
patients with sustained neutropenic fever, ARF (defined as either a doubling of serum 
creatinine or a level greater than 3 mg/dl) occurred in only 12% of patients treated with 
liposomal amphotericin B versus 26% in the conventional group 32.  
Colloids : Currently, three hypotheses are presented to explain the mechanisms of ARF 
associated with colloid use, i.e., accumulation of a low-mol weight fraction in the renal 
tubules, induction of osmotic nephrosis-like lesions (vacuolization of the proximal tubular 
cells) and hyperoncotic renal failure 33. The intratubular accumulation, hyperviscosity, 
and precipitation of low-mol wt fractions of dextran in the presence of decreased 
transglomerular filtrate seem to be specific for dextran solutions 35. The induction of 
osmotic nephrosis-like lesions has been reported for dextran as well as for gelatin and 
Hydroxy ethyl starch (HES) 33. Although these lesions were initially considered to be 
responsible for the deterioration in renal function, the significance of vacuolization of the 
proximal tubular cells remains incompletely understood because these alterations were 
also observed without accompanying ARF. The hypothesis of hyperoncotic renal failure 
which was first described by Moran and Kapsner 34 seems to explain the pathophysiologic 
considerations. The GFR depends on the imbalance between positive hydrostatic pressure 
(renal perfusion pressure) and oncotic forces at the membrane of the glomeruli. In cases 
of low renal perfusion pressure in the glomerular arterioles, an increase in the colloid 
oncotic pressure (COP) attributable to an accumulation of unfilterable, osmotically active  
 16
 
 
 
 
 
 
 
                        Figure 1  The RIFLE classification for Renal Failure (2004) 120  
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substances in the plasma,  induces reduction or cessation of glomerular filtration. The 
back-leakage of filtrate across ischemic or otherwise damaged tubular epithelium 
additionally reduces renal excretory function  33 .  
In patients with severe sepsis, the use of higher substitution  
hydroxyethylstarch (HES) was associated with a significantly higher risk of ARF than 
gelatin 36 . Voluven interferes significantly less than HAES-steril with coagulation factor 
VIII levels and partial thromboplastin time 37  .  
Though high concentrations of the colloid (10% HES) or repeated 
administration of HES with a high in vivo mol wt  increase the risk of ARF, 
hemodynamic instability, obstructive vascular disease, dehydration, and preexisting renal 
insufficiency seem to have greater predisposing effects on the development of ARF than 
does the type of colloid administered 33. HES solutions with a low in vivo mol wt, such as 
HES 200/0.5, did not increase the risk for ARF even when used in large amounts 
intraoperatively or postoperatively 38-40. 
Contrast agents : Radiographic contrast agents are thought to involve renal 
vasoconstriction; adenosine may play an important role in mediating the response 41 .  
NSAIDs: In patients with diminished renal perfusion, NSAIDs can precipitate prerenal 
azotemia 42  . 
Rhabdomyolysis and myoglobinuria: Volume depletion and an acidic urine pH 
predispose to the development of ARF, whereas volume repletion, high urine flow rates, 
and an alkaline pH are protective41. In a retrospective study of 20 patients with 
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myoglobinuria, all of whom had oliguria and azotemia despite the correction of volume 
deficits, the administration of mannitol and sodium bicarbonate was associated with 
increases in urinary output and prompt resolution of renal failure 43. Ward et al 44 through 
a multivariate analysis revealed that the presence of dehydration on presentation was an 
independent risk factor for ARF.   
There are no randomized, controlled clinical trials and many of the 
uncontrolled trials of prophylaxis against myoglobinuric renal failure have involved small 
numbers of patients. Patients with traumatic rhabdomyolysis in whom the requirement for 
crystalloid may be quite large, should undergo prompt and aggressive volume 
resuscitation.. Although the efficacy of bicarbonate and mannitol administration remains 
unproven, animal studies support their use, and in the absence of complicating factors 
such as severe hypokalemia and hypocalcemia, the risk of treatment with these agents in 
this setting is low 41.  
Cirrhosis :  Renal failure occurs in the absence of identifiable precipitants such as 
hypovolemia, infection, or treatment with nephrotoxic drugs. These patients are said to 
have hepatorenal syndrome (HRS), which is thought to arise as a result of the severe 
circulatory derangement that accompanies cirrhosis 41. 
Causes of Acute Renal Failure 
The causes of acute renal failure can be categorized as prerenal, intrinsic, and postrenal. 
(Table 5) 
 Prerenal Causes 
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Table 4 : Causes of Acute renal failure  
Pre renal   
Vomiting ,Diarrhea,Decreased fluid intake  
Increased fluid losses,Cardiac failure  
Liver dysfunction, Septic shock 
Anaesthesia.  
 
Renal  
• Toxins  : Aminoglycoside 
antibiotics,       Heme 
Pigments,Chemotherapeutic               
agents,  Myeloma proteins 
• Auto immune disorders  
• Infiltrative  diseases (sarcoidosis) 
• Infectious agents  
 
Post renal   
• Malignancy 
• Prostatic hypertrophy 
• Neurogenic bladder 
•  Intraluminal causes     bilateral 
renal calculi, papillary necrosis, 
coagulated blood,fungus,  
• Extraluminal, such as 
retroperitoneal fibrosis, tumors. 
• Intrarenal intratubular obstruction  
           various crystals, uric acid,           
calcium oxalate, acyclovir,sulfonamide, 
           methotrexate, myeloma light chain 
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Prerenal azotemia is rapidly reversible if the underlying cause is corrected. 
Elderly patients are particularly susceptible to prerenal azotemia because of their 
predisposition to hypovolemia and high prevalence of renal-artery atherosclerotic disease 
45 . The combination of angiotensin-converting–enzyme inhibitors and diuretics can cause 
prerenal azotemia in patients with large-vessel or small-vessel renal vascular disease46,47. 
Among critically ill  patients, prerenal azotemia is often due to septic shock, cardiac 
failure or liver dysfunction. 12 
 In surgical patients, prerenal azotemia is a common cause of perioperative 
and postoperative renal dysfunction. Anesthesia decreases effective blood volume and, 
when accompanied by a reduction in mean arterial pressure, can lead to a decrease in 
renal blood flow. A wide spectrum of clinical conditions can result in a generalized or 
localized reduction in renal blood flow, thus increasing the likelihood of ischemic acute 
renal failure. The most common condition leading to ischemic acute renal failure is 
severe and sustained prerenal  azotemia.  
Intrinsic Causes 
Intrinsic renal diseases that result in acute renal failure are categorized according to the    
primary site of injury: tubules, interstitium, vessels, or glomerulus. Injury to the tubules is 
most often ischemic or toxin induced. Prerenal azotemia and ischemic tubular necrosis 
represent a continuum, death of tubular cells. Many clinical conditions can lead to kidney 
ischemia as a result of either extrarenal or intrarenal factors that compromise renal blood 
flow. Although most cases of ischemic acute renal failure are reversible if the underlying 
cause is corrected, irreversible cortical necrosis can occur if the ischemia is severe,  
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Most common mechanisms of abnormal renal blood supply in acute renal 
failure 
 
 
 
Figure 2 
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especially if the disease process includes microvascular coagulation such as may occur 
with obstetrical complications, or the hemolytic–uremic syndrome 48. Acute renal failure 
due to acute interstitial nephritis is most often caused by an allergic reaction to a drug 49. 
Postrenal Causes 
Acute renal failure occurs when both urinary outflow tracts are obstructed or 
when one tract is obstructed in a patient with a single functional kidney. Postrenal causes 
are important to rule out quickly, since the potential for recovery of renal function is 
often inversely related to the duration of obstruction 50. 
 
V  Pathogenesis of ARF  
Prerenal azotemia and ischemia are common causes of ARF.  In addition, 
toxins that cause tubular necrosis share many pathophysiologic features with ischemic 
acute renal failure. Vasoconstriction, desquamation of tubular cells, intraluminal tubular 
obstruction, and transtubular back-leakage of the glomerular filtrate are pathophysiologic 
mechanisms that have been well characterized 51. 
Vascular Factors  
Intrarenal vasoconstriction caused by an imbalance between 
vasoconstrictive and vasodilative factors may result from systemic or local vasoactive 
agents that act on the small vessels of the kidney. The resulting ischemia can directly 
alter endothelial-cell function, decreasing the production of and response to vasodilative 
substances 51. 
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Fig 3: Morphologic changes occurring in the proximal tubule after ischemia and   
 
reperfusion 
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Renal Medullary Hypoxia 
Heterogeneity of intra renal blood flow contributes to the pathophysiology 
of ischemic acute renal failure. An imbalance between the vasodilator nitric oxide and the 
vasoconstrictor endothelin may also impair medullary blood flow and contribute to 
tubular-cell damage. In the outer medulla, where tubules have high oxygen requirements, 
ischemia causes swelling of tubular and endothelial cells as well as adherence of 
neutrophils to capillaries and venules. These changes lead to vascular congestion and 
decreased blood flow, tipping the tenuous balance between oxygenation and energy 
demand 52,53 .  
Structural Changes and Tubular-Cell Injury 
A hallmark of ischemic and toxic acute renal failure is injury and death of 
tubular cells. The pathophysiologic events leading to the death of necrotic tubular cells 
are complex. After ischemia and reperfusion, morphologic changes occur in the proximal 
tubules, including loss of the brush border, loss of polarity, and redistribution of integrins 
and Na+/K+–ATPase to the apical surface. Calcium, reactive oxygen species, purine 
depletion, and phospholipases probably have a role in these changes in morphology and 
polarity, as well as in the subsequent cell death that occurs as a result of necrosis and 
apoptosis. There is a sloughing of viable and nonviable cells into the tubular lumen, 
resulting in the formation of casts and luminal obstruction and contributing to the 
reduction in the glomerular filtration rate (Fig 3). The severely damaged kidney can 
completely restore its structure and function. Spreading and dedifferentiation of viable 
cells occur during recovery from ischemic acute renal failure which duplicates aspects of 
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normal renal development. A variety of growth factors have been shown to probably 
contribute to the restoration of a normal tubular epithelium.   
 
Biochemical Changes 
Calcium 
Depletion of cellular ATP, which accompanies ischemia, leads to an 
increase in the cytosolic calcium concentration in cells 54. In addition to its 
vasoconstrictive effects, calcium can contribute to epithelial-cell toxicity through its 
ability to activate proteases and phospholipases, break down the cytoskeleton, and 
interfere with mitochondrial energy metabolism. Although increases in calcium occur 
soon after hypoxia in experimental systems 54, there remains some controversy about the 
extent to which increased intracellular calcium causes the ischemic tubular-cell injury.   
Reactive oxygen species 
Partially reduced species of oxygen can cause marked tissue injury. With 
the restoration of oxygen after a period of ischemia there is a rapid burst of oxidant 
formation. The sources of these oxidants in the kidney include cyclooxygenases, 
mitochondrial electron transport, mixed-function oxidases of the endoplasmic reticulum, 
the xanthine oxidase system, and neutrophils. The role of reactive oxygen species in 
ischemic acute renal failure remains in question. Some studies in animals show that 
antioxidants or scavengers of reactive oxygen species protect against functional tissue 
damage, whereas other studies do not 55.  
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Purine depletion 
Ischemia leads to the breakdown of ATP and the formation of adenosine, 
inosine, and hypoxanthine, all of which can leak out of cells, constrict intrarenal 
arterioles, and contribute to the formation of reactive oxygen species 55. Although in one 
study ATP and magnesium protected against ischemic injury in rats 56, other experiments 
showed that ATP injured oxygenated proximal tubules and was vasoconstrictive 57.  
Phospholipases 
Phospholipase A2, a family of enzymes that hydrolyze phospholipids to 
free fatty acids and lysophospholipids can contribute to ischemic cellular injury in 
various organs 55. Activated phospholipase A2 can alter the permeability of cell and 
mitochondrial membranes, disturbing the bioenergetic capacity of the cell. Peroxidation 
of membrane lipids due to ischemia and reperfusion enhances the susceptibility of 
membranes to phospholipase A258. In addition, arachidonic acid, a product of 
phospholipase A2, is converted to eicosanoids that are vasoconstrictive and chemotactic 
for neutrophils. No specific inhibitors of phospholipase A2 are available for use in 
humans.  
 Apoptosis 
Pathological evidence of apoptosis has been found in postischemic 
kidneys in animals 59 and in clinical acute renal failure in humans55. Apoptosis seems to 
be particularly prevalent in post-transplantation acute renal failure, where it coexists with 
necrosis    60.  
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Neutrophil chemotaxis  
The adherence of neutrophils to the vascular endothelium is an essential 
step in the extravasation of these cells into ischemic tissue. Chemotaxis of neutrophils is 
partly due to the activation of the complement cascade, with local formation of C5a. 
After adherence and chemotaxis, neutrophils release reactive oxygen species, proteases, 
elastases, myeloperoxidase, and other enzymes that damage the tissue. These substances, 
together with leukotriene B4 and platelet-activating factor, can both increase vascular 
permeability and up-regulate the expression of adhesion molecules that promote further 
inflammation. In models of renal, myocardial, and intestinal ischemia, the depletion of 
neutrophils, blockade of neutrophil adhesion to the endothelium, and inhibition of the 
complement system all reduce tissue injury 61-66.  
Intercellular adhesion molecule 1 (ICAM-1) on endothelial cells interacts 
with CD11a/CD18 and CD11b/ CD18 on neutrophils, promoting the adhesion of 
neutrophils to endothelial cells 61. The administration of a monoclonal antibody directed 
against ICAM-1 protects animals from ischemic acute renal failure, even when given two 
hours after the ischemic event 67. In addition, mice with a deficiency of ICAM-1 are 
protected against acute renal failure 65. Antibodies against ICAM-1 have been 
administered safely to allograft recipients in a phase 1 trial 68  . 
 Acute Renal Failure in Transplant Recipients 
Ischemic injury to an allograft from a cadaveric donor can lead to delayed 
graft function, which has been associated with acute rejection and decreased graft 
survival 69,70. Extensive local release of cytokines, complement activation, and increased 
expression of MHC class I and II molecules occur as a result of kidney ischemia. 71,72. 
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Furthermore, at the site of ischemia, local production of tumor necrosis factor and 
complement fragments induces the expression of selectins and ICAM-1 on endothelial 
cells. Preliminary studies with antagonists of platelet-activating factor and antibodies 
against ICAM-1 suggest that platelet activation and leukocyte–endothelial-cell 
interactions may be important in early post-transplantation renal failure and rejection in 
humans64,68 . In the future, other approaches to decrease ischemic injury and rejection in 
the allograft may include the use of complement inhibitors, anticytokine agents, or 
endothelin antagonists  73 . 
Pathophysiology of ARF 
Direct consequences 
Direct consequences are related to the decreased production of 
erythropoietin and the retention of organic or inorganic wastes that are normally excreted 
by the kidneys.  
Uremic retention  
Though well described in chronic renal failure,  uremic toxicity may occur 
irrespective of the levels of urea in the blood . Urea may not cause toxicity on its own. 
Serum urea is probably a marker for other compounds that may cause toxicity. Uremic 
toxicity in patients cannot be extrapolated to patients with ARF 74. 
Anaemia  
Decreased erythropoietin levels or erythropoietin resistance secondary to 
infection are responsible for decreased bone marrow synthesis of the vital precursors. 
Uremia induced fragility of the red cell membranes leads to decreased half lives. Uremic 
coagulopathy leads to increased blood loss. 
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Table 5 : Pathophysiology of ARF 
 
 
 
 
 
 
 
 
 
 
 
 
Direct consequences Retention of compounds  
• Organic compounds- uremic toxicity 
• Inorganic compounds – water and 
electrolytes 
Decreased production of metabolites- erythropoietin  
Indirect consequences Side effects of treatment for ARF 
• Side effects of Drug therapy 
• Side effects of Renal replacement therapy 
• Adverse drug reactions  
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Fluid balance  
The BEST (beginning and end supportive therapy) trial for patients 
showed a use of diuretics for more than 70% of their patients. In many patients an 
important reason for initiating renal replacement therapy is the onset of volume overload 
and oliguria. Volume over load has been seen to cause increased complications and in 
fact a negative impact on the outcome of patients coming for surgery as shown in the 
beneficial circumstances of improved recovery in the fluid restricted arm, amongst a 
cohort under going major colorectal surgery 74. 
Electrolyte abnormality 
Impaired free water clearance cause dilutional hyponatremia in patients 
with acute renal failure. Hyponatremia results in osmotic imbalances causing swelling up 
of cells (mainly neurologic) resulting in a wide range of symptoms from headache to 
coma. The rapidity of onset of hyponatremia is directly related to increased likelihood of 
symptoms 75. In addition to conditions which cause a shift of potassium ions from the 
intracellular compartment, such as acidosis, rhabdomyolysis and hemolysis, the failure to 
excrete potassium results in an accumulation of potassium ions in the extra cellular 
compartment 74. 
Acid Base Status 
When kidney function is decreased there occurs an accumulation of 
organic and unmeasured ions.  There occurs decreased production of bicarbonate by 
decreased proximal tubular reabsorption and regeneration. Metabolic acidosis is 
accentuated by decreased buffering capacity secondary to hypoalbuminemia .Non renal 
etiologies of metabolic acidosis such as lactic acidosis, respiratory acidosis caused by 
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permissive hypercapnia, ventilation and ketoacidosis seem to compound the effect of 
mixed disorders 76. 
Increased inflammation  
The normal inflammatory reaction seems to be dysregulated in acute renal 
failure and this seems to be the cause of the ensuing multi organ failure in may of the 
patients admitted in the intensive care unit. Pro inflammatory mediators such as tumor 
necrosis factor and interleukin 1 beta , 6 and 8 have increased levels in patients with ARF 
as compared with normal  patients or patients with end stage renal failure. The level of 
interleukin 10 is also increased suggesting an inflammatory anti response .After ischemia, 
reperfusion of the kidneys causes a dysregulation in the salt and water channels and 
increased vascular permeability in the lungs leading to interstitial edema 77. 
Dysregulation of the lung and water channels has been related to the 
severity of ARF suggesting that uremia may be responsible. There is considerable 
evidence to show that ARF is caused at least in part by an inflammatory cascade of 
events. It has been postulated that this inflammatory response is likely to be the cause of 
generalized inflammation and organ dysfunction. 
The type  of acidosis may also seem to affect the degree of inflammation, 
be it respiratory, metabolic, hyperchloremic or lactic. Hyperchloremic acidosis is more 
pro inflammatory than lactic acidosis. In vivo acidosis leads to increased nitric oxide 
levels and lower blood pressure value. A decrease in gut barrier function and an increase 
in lung and intestinal injury have been documented. 
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Decreased immunity 
Since ARF patients also experience uremia it is possible that these patients 
also have some degree of immune suppression. Normal leukocyte, neutrophil, and 
lymphocyte  function is affected by acidosis as well as uremic retention compounds like 
leptin, advanced glycation end products, guanidine and p – cresol. Other factors such as 
malnutrition, iron overload, anemia and bio incompatibility of dialyser membranes which 
are commonly associated with chronic uremia may also be seen in the setting of acute 
renal failure 78.  
Cardiovascular changes 
Though hypotension and shock are the findings one would commonly tend 
to see in the setting of acute renal failure, hypertension can also be occasionally seen in 
patients with volume overload and increased intravascular volume. Volume overload may 
cause congestive cardiac failure and subsequently hypotension. Intra abdominal 
hypertension may occur as a result of ascites, retroperitoneal tissue edema and increasing 
intra abdominal pressures. The resulting compression of the inferior vena cava may result 
in decreased filling pressures and hence a drop in the cardiac output. Abnormal lung 
function due to decreased functional residual capacity caused by the upward shift of the 
diaphragm, may result. Decreased perfusion of the intra abdominal organs and ileus  will 
accompany liver and kidney malfunction.  
Moderate hypochloremic acidosis increases nitric oxide levels and 
inducible nitric oxide synthase leading to lower blood pressure values. Hypotension ands 
shock are compounded by preexisting co morbidities seen a good number of critically ill 
patients, such as anemia and coronary artery disease 79.  
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Pulmonary function  
Volume over load may cause pulmonary congestion, pleural effusions or 
intra abdominal hypertension leading to impaired gas exchange. Dysregulation of the 
inflammatory cascade and increased vascular permeability may result in interstitial 
edema. Increased incidence of infections and pneumonia may ensue. Needless to say loss 
of muscle mass and over sedation may prolong the duration of mechanical ventilation. 
Neuromuscular disease 
Increased muscle breakdown, and decreased protein metabolism lead to 
decreased muscle mass. Polyneuropathy though more common in patient with chronic 
renal failure can also be seen patients with ARF. Difficulty in weaning off from 
mechanical ventilation may be a consequence of the above. 
Infection  
Studies show that infections could lead to as much as 40% of the mortality 
in patients with acute renal failure. Acidosis related insulin resistance and anaerobic 
glycolysis is associated with decreased immune dysfunction and increased susceptibility 
to infection. Insulin resistance induced hyperglycemia has been described to be an 
important risk factor for multi organ dysfunction and death in critically ill patients. Tissue 
edema may delay wound healing and increases the risk of infections 80. 
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VII. Management of Acute Renal Failure 
Diagnosis  
The diagnosis of renal failure using the serum creatinine, and creatinine 
clearance levels have already been discussed above. A few old as well as new modalities 
which can help in the diagnosis and classification of ARF. 
Fractional excretion of sodium  
The Indications for using this modality of investigation include Renal 
Failure Assessment in prerenal  azotemia and acute tubular necrosis  . If the  FENa is less 
than <1% it would most likely indicate prerenal azotemia.it would also be consistent with 
a spot Urine Sodium <30 meq/L . If the FENa >2%: Acute Tubular Necrosis (ATN) 
could be the diagnosis made and it would be consistent with spot Urine Sodium >30 
mEq/L . It is said to have certain disadvantages . FENa is invalidated by diuretics. FENa 
has to be delayed until 6-8 hours after the last diuretic dose, and can be found to be low 
despite presence of ATN  in certain subsets of patients with ARF (such as with post- 
ischemic ATN ,use of IV contrast, acute glomerulonephritis and vasculitis) 81.  
Urine spot sodium  
Urine sodium concentration is used to determine the cause of 
hyponatremia and help guide therapy. A spot test showing urine sodium concentration of 
less than 30 mEq/L differentiates patients with hypovolemic hyponatremia from patients 
with euvolemic hyponatremia. A high urine sodium concentration may be found in 
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patients with volume depletion secondary to a renal cause of salt wasting (eg, adrenal 
insufficiency, thiazidediuretic use), metabolic alkalosis or osmotic diuresis (eg, from 
hyperglycemia). Nephrotic syndrome, congestive heart failure and cirrhosis typically 
have a low urine sodium concentration unless patients are taking a diuretic, whereas renal 
failure tends to cause a high urine sodium concentration  82. 
Urinary Para Amino Hippuric acid (PAH) clearance, traditionally used as a test of 
renal plasma flow may grossly underestimate renal plasma flow in those with ARF 83. 
Total renal plasma flow measured by alternate techniques, is close to normal during the 
extension, maintenance, and recovery stages of ischemic renal injury.  
Techniques of Measurement of GFR in Patients with ARF 
GFR is commonly measured using plasma or renal clearance of marker 
solutes administered as a bolus or continuous infusion. The reference standard is renal 
inulin clearance but other solutes commonly used include radioactive (125I-iothalamate, 
51Cr-EDTA) or non-radioactive markers (iothalamate, iohexol, polyfructosan). 
Paramagnetic agents (gadolinium DTPA) are rarely used. GFR can be measured by 
various methods including the continuous infusion method (IM), the standard clearance 
method (CM) or the plasma clearance method 84.  
Continuous Infusion Method without Urine Collection 
This method is not suitable for use in patients with ARF 84 in view of the 
unstable GFR in these patients. 
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Standard Clearance Method with Urine Collection 
   This method lends itself well to estimation of GFR in ARF when 
hemodynamic changes can be rapid. By collecting urine and plasma at timed intervals, 
rapid changes in GFR can be detected 84. 
Radioactive Markers  51Cr-EDTA and 99m Technetium-diethylene triamine penta 
acetic acid (99mTc-DTPA) have been used. Plasma clearance showed an excellent 
correlation with simultaneous GFR measurements performed with a standard 125I-
iothalamate clearance technique. Renal function was monitored in patients at risk for ARF 
during angiography or in the intensive care unit under noninvasive and near real-time 
conditions. The results indicate that the technique detects rapid changes in renal function 
with a resolution time of 5 min in patients with normal renal function, and 15 min in 
patients with severely impaired renal function.  
Pitfalls  in the measurement of GFR)  in ARF 
Measurement and estimation of GFR in ARF presents numerous 
challenges. Serum creatinine concentration alone will provide inaccurate information of 
estimated GFR when the GFR is rapidly changing or before it reaching an equilibrium 
value. Urinary clearance of GFR markers may provide better information. Thus, if a bolus 
of a marker such as inulin was administered intravenously and its urinary clearance 
measured, an estimate of GFR can be obtained.  
The choice of the GFR marker such as inulin, 125-I iothalamate, and 
others has been validated in patients with stable renal function. Increased transcapillary 
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hydraulic pressure gradient and tubular dilatation was the predominant cause of persistent 
renal failure in patients with ischemic transplanted kidneys 86. Leakage of substances 
filtered at the glomerulus but which leak back across the tubular epithelium, may 
underestimate GFR in ARF. Olbricht et al 85 measured the permeability to those 
substances most commonly used for filtration rate determination, such as polyfructosan 
and inulin, by measuring their recoveries after perfusion through various nephron 
segments in ischemic and nephrotoxic models of ARF in animals. Distal recovery of 
polyfructosan and inulin were reduced by a maximum of 11%, and urinary recovery of 
inulin was reduced by only 15% in kidneys showing severely restricted renal function. 
Thus the reduction in whole kidney inulin or polyfructosan clearance reflects primarily a 
reduction in GFR, although there is also a small component of back leak. 
CystatinC: It is a cysteine protease inhibitor of low molecular weight and is produced 
constantly by nucleated cells, is excreted by the glomerulus and thus closely reflects 
GFR, and may well be a better marker of GFR than creatinine 87. 
Magnetic Resonance Imaging in Acute Renal Failure 
 
Recent technical developments in contrast  MRI have permitted ultrafast 
imaging with short acquisition times. Gadolinium-chelates are non-nephrotoxic, freely 
filtered by the glomerulus, and not reabsorbed or secreted by the tubules 88and are well 
suited to assess GFR. Besides detection of urinary tract obstruction or renal parenchymal 
abnormalities, vascular, especially arterial, morphology is accurately and rapidly assessed 
from the supra-aortic to the distal peripheral arteries in one diagnostic procedure. This is 
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of interest, as patients with ARF may also suffer from atherosclerosis or abdominal aortic 
aneurysms or may present with renal arterial or venous obstruction or occlusion. 
The loss of corticomedullary differentiation is a sign of changing 
differential perfusion to the renal cortex and medulla in ARF.  MRI may be valuable to 
distinguish vascular complications and acute allograft rejection after renal 
transplantation. Blood oxygenation level-dependent (BOLD) contrast MRI depends on the 
principle that hemoglobin (because of its iron content) changes its magnetic qualities 
depending on whether hemoglobin is in the deoxygenated or the oxygenated form. 
Deoxyhemoglobin shows paramagnetic, oxyhemoglobin diamagnetic effects in the 
magnetic field. Therefore, deoxyhemoglobin acts as an endogenous contrast agent, and 
increased deoxyhemoglobin concentration leads to signal attenuation in T2 weighted MR 
sequences. Because the ratio of deoxyhemoglobin to oxyhemoglobin is related to the pO2 
of blood, which again is thought to be in equilibrium with the surrounding tissue, BOLD 
MRI can noninvasively estimate tissue pO2 in humans. BOLD MRI measures intrarenal 
oxygenation and not perfusion and  cannot distinguish between alternating oxygenation 
induced by changing perfusion or by oxygen consumption 89 . 
Prevention of Acute Renal Failure in the Critically Ill 
Prerenal azotemia and acute tubular necrosis (ATN) are the most frequent 
causes of ARF in ICU. Preventive strategies should focus on methods that may augment 
renal perfusion or reduce renal oxygen consumption.  
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Low-dose dopamine is known to result in renal artery dilatation, natriuresis, and 
diuresis. Low-dose dopamine continues to be widely used to protect against ARF and 
ameliorate established ARF without much benefit. (Table -6)  
Fenoldopam is a specific DA-1 receptor agonist. In a study involving fenoldopam 
(Prospective, double-blind, placebo-controlled trial) continuous infusion of fenoldopam 
(n = 150) at 0.09 microg x kg x min the incidence of ARF was significantly lower in the 
fenoldopam group compared with the control group (29 vs. 51 patients; p = .006). The 
length of intensive care unit stay in surviving patients was significantly lower in the 
fenoldopam group compared with the control group (10.64 +/- 9.3 vs. 13.4 +/- 14.0; p < 
.001. Compared with placebo, low-dose fenoldopam resulted in a smaller increase in 
serum creatinine in septic patients 41. 
Osmotic Agents and Diuretics: Mannitol, furosemide and bumetanide have also been 
used to increase intratubular flow rates. Mannitol and other osmotic agents help preserve 
transplanted kidneys ex vivo and prevent delayed graft function, which is most often 
caused by ischemia 91.  Mannitol has been used along with vigorous volume replacement 
and sodium bicarbonate, for the prevention and treatment of early myoglobinuric acute 
renal failure 92. This agent is also used together with adequate hydration in an attempt to 
prevent the nephrotoxic effects of cisplatin 41.  
Although mannitol and furosemide have been shown in animals to help 
protect the kidney against ischemic injury most studies in humans have failed to 
demonstrate the effectiveness of these agents in the prevention or treatment of ischemic 
or toxic acute renal failure 93,94. 
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                         Table – 6: Studies involving Dopamine41 
 
 
 
 
 
 
 
Author  Design  Patient 
population  
Outcomes Dose of 
dopamine  
Conclusion  
Swygert 
et al 
Randomized 
double blind 
placebo 
controlled 
Liver 
transplant 
Urine 
output  
BUN/serum 
creatinine 
3 mcg/kg/min Inconclusive 
Baldwin 
et al  
Prospective 
Randomized 
double blind 
placebo 
controlled 
Abdominal 
aortic 
aneurysm 
Aorto 
femoral 
grafting  
Serum 
creatinine/ 
BUN/ 
Creatinine 
clearance  
3 mcg/kg/min No benefit  
Kadiera 
et al  
 
Prospective 
controlled  
Kidney 
transplant  
Graft 
function 
1 week 
3 months  
post 
surgery  
3 mcg/kg/min Inconclusive 
Chertow 
et al  
Randomized 
placebo 
controlled 
ARF Dialysis 
Death   
>3mcg/kg/min 
<3mcg/kg/min 
 
Inconclusive 
Bellomo 
et al  
Randomized 
placebo 
controlled 
ARF in ICU Serum 
creatinine  
2 mcg/kg/min No 
significant 
improvement
Abiziad 
et al  
Prospective 
Randomized  
CRI 
undergoing 
coronary 
angiography 
Serum 
creatinine  
Dialysis  
2 mcg/kg/min No 
improvement
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Both mannitol and loop diuretics, if administered early in the course of 
ischemic ARF can convert an oliguric to a nonoliguric state. Although nonoliguric acute 
renal failure is generally associated with a lower mortality rate, there is little evidence 
that conversion from an oliguric to a nonoliguric state decreases the mortality rate 41. 
Diuretics can be detrimental in acute renal failure induced by radio contrast agents  95-97. 
In the setting of cardiovascular surgery diuretics are used to decrease renal oxygen 
consumption and to prevent the accumulation of intraluminal debris that may cause 
obstructing casts. Conger found no evidence to support use of prophylactic mannitol in 
non transplant surgery 98. In a small study of cardiac surgery patients, prophylactic use of 
furosemide infused at 0.5 µg/kg/min was associated with significant worsening of renal 
outcome compared with placebo 97. 
Atrial natriuretic peptide (ANP) is a potent diuretic and natriuretic substance. A 48-h 
infusion of ANP was found to improve renal blood flow and GFR 99. In a study of 
504 critically ill patients with ATN, even though there was no effect of a 24-h infusion of 
a synthetic ANP, on dialysis-free survival, analysis demonstrated that in patients with 
oliguria, there was a 27% dialysis-free survival compared with only 8% in the placebo 
groupIn non oliguric patients dialysis-free survival was 48% versus 59% in the control 
group 100. Another study of 222 oliguric patients with ATN treated with ANP for 24 h 
found a nonsignificant trend toward improvement in 14-d and 21-d dialysis-free survival, 
but 60-d mortality rates were similar 101.  
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Volume expansion and vaso active drugs  
In a nonrandomized study of 56 patients with sepsis and hypotension, the 
addition of nor adrenaline  to low-dose dopamine was associated with an increase in the 
mean creatinine clearance from 75 to 102 ml/min 102.Nor adrenaline infusions in septic 
animals have been shown to induce increased renal blood flow in animals 103. Gattinoni L  
et al in their multicenter study, therapy (volume expansion and vasoactive drugs) aimed at 
achieving supranormal values for the cardiac index or normal values for the mixed 
venous oxygen saturation had no effect on the frequency or severity of renal dysfunction 
104. No randomized control trial has compared fluids with no  intervention, but fluids 
resuscitation does have benefit especially in situations such as traumatic rhabdomyolysis.  
Free radical scavenging:  
Free oxygen radical injury is believed to be an important component of SIRS, and 
selenium-dependent glutathione peroxidase is one of the main free radical scavenging 
systems 41. The role of selenium deficiency and replacement was explored in a 
randomized trial of 42 ICU patients diagnosed with SIRS whose mean selenium levels 
were approximately 40 to 50% of the normal values 105. In the group assigned to receive 
repletion with intravenous sodium selenite, the mean creatinine concentration was 
significantly lower and only 3 of the 21 patients required continuous venovenous 
hemodialysis, compared with 9 of the 21 control patients. Mortality was also reduced in 
the selenium repleted group particularly in those with the highest Acute Physiology and 
Chronic Health Evaluation III (APACHE III) scores (36% versus 89%). No side effects of 
the selenium repletion regimen were recognized. 
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Corticosteroids may hasten the recovery of renal function during acute interstitial 
nephritis 41, but their role remains controversial because controlled studies are lacking 
and corticosteroids may be contraindicated in patients with underlying infection.  
Ischemia reperfusion renal injury and N Acetyl Cysteine (NAC) 
The exact mechanism by which NAC may prevent renal contrast induced 
nephropathy (RCIN) is unknown, although antioxidant and vasodilatory effects likely 
play a key role. NAC directly scavenges oxygen free radicals and also serves as a 
precursor of glutathione, itself a natural antioxidant. In addition NAC increases the 
concentrations of both nitric oxide, a potent but short acting vasodilator, and S-
nitrosothiol which has more prolonged vasodilatory effects 106. 
The beneficial effects of NAC on the outer medullary circulation may be 
dependent not only on free radical scavenging but also on NO potentiation, both of them 
promoting vasodilatation and preventing leukocyte activation and leukocyte-endothelial 
adhesion and, ultimately, precluding the endothelial dysfunction associated with 
ischemia-reperfusion processes 107.  
Liver disease  
Hepato renal syndrome (HRS) is a major cause of mortality in the 
critically ill.  Sort et al randomized patients to determine the effect of albumin and renal 
impairment, defined by the study investigators as a greater than 50% rise in blood urea 
nitrogen or creatinine. Renal impairment occurred in only 10% of the patients receiving 
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albumin compared to 33% in the other group. The administration of albumin was also 
associated with a significant reduction in mortality 108. 
Several recent studies have examined the effect of splanchnic vasoconstrictors like 
ornipressin  in patients with HRS. 3 days of low-dose vasopressin led to significant 
increases in urinary flow but GFR actually decreased 109,110. 
Supportive measures till recovery  
Renal Replacement Therapy (RRT) and its Adequacy  
Intermittent HD remains the dominant mode of RRT all over the world, used in more 
than two-thirds of cases in recent surveys.  
Indications  
• Features of uremia  
• Hyperkalemia refractory to medical management;  
• Volume overload unresponsive to fluid restriction and diuretics;  
• Metabolic acidosis that is severe or accompanied by volume overload,  
• Precluding adequate bicarbonate therapy;  
• Certain dialyzable intoxications (e.g., lithium, toxic alcohols, salicylate,digoxin) 
• Hypocalcemia, hyperphosphatemia, or hypercalcemia  
• anuric ARF unresponsive to acute interventions  
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Classification of renal replacement therapies  
Renal replacement therapies currently available include intermittent HD, 
peritoneal dialysis, and various forms of CRRT. CRRT techniques are classified 
according to the driving force for blood flow (spontaneous/arteriovenous or pumped/ 
venovenous techniques) and the predominant solute transport process employed.  
Solutes that are small enough may be transported with water(solvent drug) 
across a semipermeable membrane by convection. Ultrafiltration occurs when water is 
driven across a membrane by a pressure gradient. Slow continuous ultrafiltration (SCUF), 
with ultrafiltration rates of 200 ml/h does not cause significant solute clearance. When 
hemofiltration is performed for uremia therapy however, increased hourly ultrafiltration 
rates of 1-2 L/h are customary and urea clearance by continuous arteriovenous (CAVH) 
or venovenous (CVVH) hemofiltration is substantial. During hemofiltration, 
administration of "replacement fluid" containing buffer (bicarbonate or lactate) and 
various electrolytes (sodium, potassium, calcium, magnesium, phosphorus) prevents 
iatrogenic acidosis and electrolyte depletion and further lowers the plasma concentration 
of uremic solutes by hemodilution, augmenting the effect of simple transmembrane urea 
clearance. The most complex form of CRRT combines convective and diffusive solute 
transport during continuous hemodiafiltration (CAVHDF or CVVHDF).  
The precise timing of RRT initiation is usually a matter of clinical 
judgment.  This pattern of practice is based primarily on early experience suggesting that 
uremic bleeding diathesis and hemorrhage were reduced when hemodialysis was initiated 
before the BUN exceeded 100 mg/dl 111. 
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Intermittent versus continuous renal replacement therapy 
CRRT is most frequently used in patients who are hemodynamically intolerant of 
intermittent HD usually because of sepsis or severe cardiac dysfunction. Control of 
azotemia with venovenous CRRT is possibly superior to daily intermittent HD in large or 
hypercatabolic patients 112. 
Anti coagulation in CRRT 
CRRT without anticoagulation may be successful in some coagulopathic 
patients such as those with end-stage liver disease. In many septic patients with 
thrombocytopenia and elevated prothrombin time/partial thromboplastin time (PT/PTT) 
due to diffuse intravascular coagulation (DIC), increased filter clotting is the rule if no 
anticoagulation is used. In newly postoperative patients and others with contraindications 
to systemic anticoagulation, regional anticoagulation of the hemofilter alone is preferred.  
Biocompatibility  
Biocompatible membranes are more expensive but data does not suggest any clinical 
adverse effect of their use in severe ARF, which is likely to continue unless proven 
ineffective or harmful by a major prospective trial. 
Dose of renal replacement therapy  
Clearance of urea, a low molecular weight nitrogenous waste product is the most 
commonly studied marker of adequate uremic detoxification by HD. The term Kt/V is a 
unitless measure of HD dose (based on urea removal): K is the urea clearance of  
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Therapeutic goal  Hemodynamic condition  Preferred renal replacement 
therapy 
Urea clearance Stable  
Unstable  
Intermittent hemodialysis 
CRRT 
Convection-CAVH,CVVH 
Diffusion – 
CAVHD,CVVHD 
Both- CAVDHF,CVVHDF 
 
 
Severe hyper kalemia 
 
 
Stable /unstable 
 
Intermittent hemodialysis 
Severe metabolic acidosis Stable  
Unstable  
Intermittent hemodialysis 
CRRT 
 
Severe hyper phosphatemia 
 
 
Stable/unstable  
 
CRRT 
Fluid removal  Stable 
Unstable  
Intermittent isolated 
ultrafiltration 
Slow continous 
ultrafiltration or peritoneal 
dialysis  
 
 
 
 
 
Table 7: Indications for different modes of RRT 
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the dialysis membrane used (ml/min), t is the duration of dialysis (min), and V is the 
volume of distribution of urea in the patient (ml). Thus, Kt/V is a measure of the volume 
of plasma cleared of urea during an HD session (Kt) divided by the urea distribution 
volume (V, assumed to be total body water: 0.5-0.6 L/kg), and larger Kt/V values signify 
greater HD dose. Kt/V measurements of delivered dialysis dose are usually calculated 
using the ratio of postdialysis to predialysis BUN and a nomogram 113. 
Dialysis Outcomes Quality Initiative recommendations defined a Kt/V of 
1.2 as the minimum acceptable dialysis dose in chronic HD patients. No such dosing 
guidelines have been established for the ARF population. 
Results of a prospective, observational studies show that  68% of ARF 
treatments failed to deliver the minimum dialysis dose recommended for maintenance HD 
of renal failure patients and for 49% of treatments a minimally adequate dialysis dose was 
not even prescribed. Failure to adjust dialysis dose and/or achieve adequate dialysis 
delivery in larger patients was a major source of treatment failure 113. 
In a study by Schiffl daily intermittent HD was associated with a markedly lower 
mortality than alternate day therapy (21 versus 47%, p < 0.025) in a group of 72 ICU 
patients with ARF 114. Simple interventions should include use of anticoagulation 
whenever possible (to minimize loss of dialyzer surface area), replacement of catheters 
with suboptimal blood flow rates, and most importantly, prescription of an increased 
dialysis dose for larger patients.  
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VIII    Outcome  
Mortality in acute renal failure  
Reported ICU mortality rates in patients with ARF vary between 20 and 
70%. Although some studies say that only pronounced impairment of renal function was 
associated with significant morbidity and mortality, other studies have shown that slight 
increases on serum creatinine >0.5mg% in post operative patients have been associated 
with increased mortality 115. As far as change over the last few decades of mortality   in 
patients with acute renal failure few studies have reported a decline in rates while using 
similar criteria. McCarthy et al 116 in their retrospective comparison of 71 consecutive 
ICU patients with ARF during two decades showed a significantly improved rate of 
hospital survival (52% versus 32%) and 1-year survival (30% versus 21%). The mean 
total APACHE II score was the same in both study periods.  
The results of various mortality studies are as given in table 8. Limitations 
of these mortality studies the should be noted that although use of ICD-9-CM codes for 
identification of ARF has been shown to be valid by a previous study 117 sensitivity was 
low (15%), suggesting that ARF figures that are recorded is likely underreported. A 
recent study indicated that approximately 80% of patients with biochemical criteria for 
ARF were not identified by ICD-9-CM code 19. If these findings are applicable to the 
general population, then the magnitude of underestimations in this study could be up to 
five- or six-fold.  
Several recent studies have shown two fold higher mortality rates between 
patients who had ARF and required RRT as against those who had ARF but did not  
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Study  Type of study  Mortality rate/circumstance  Year  
Hou and colleagues 18 Prospective  25% 1979 
Mcarthy et al 116 Retrospective  52% 1977 
Sushrut et al 133 Retrospective  40.4% 1988 
Mcarthy et al 116  Retrospective  32% 1992 
Liano et al 6 Prospective  45% 
65%- subset requiring dialysis 
1996 
Brivet et al 128 Prospective  58% 1996 
Ralph et al128  Prospective  68%- Intermittent hemodialysis 
75%-CVVHD 
1996 
Hou and colleagues 12 Prospective  19% 1996 
Schwilk et al  Prospective  12% -one failing organ system 
38% with two OSF, 
 72% with three OSF,  
90% with four OSF  
100% with five OSF 
1997 
Lombardi et al128  Retrospective   1998 
Mangano et al134  Prospective  63% post myocardial          
revascularization  ARF 
1998 
Mendonca et al2  Prospective  42% 2000 
Clermont et al 4 Prospective  57% 
75% - subset requiring dialysis  
2002 
Mehta et al 131 Retrospective  51.5% 2002 
Mehta et al 131 Retrospective  53%- with use of diuretics 2002 
Sushrut et al133  Retrospective  20% 2002 
Hoste et al 22  Retrospective  56.7%- with sepsis  2003 
Schrier et al 23 Prospective  70% - with sepsis  2004 
Uchino et al 123  Prospective  60.3% 2005 
Liangos et al 21  Retrospective  22.3% 2006 
 
Table 8: Mortality rates compared from literature128 
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require RRT. The difference was four fold when a critically ill population without ARF 
was compared with those who required RRT 115. An important finding of prognostic 
relevance is that ARF in the ICU is associated highly with the development of multi 
organ failure.   
 A study by the Madrid group 20 which has assessed ARF in the above 80 
age group showed that the  relative risk for mortality in patients aged more than 80 years 
was 1.09 [95%CI 0.86,1.36 (P = .562)], and in those aged 65 to 79 it was 0.99 [95%CI 
0.83,1.18 (P = .954)] compared with patients aged less than 65 years.                              
Patients with "community-acquired ARF" (i.e., patients in whom ARF was 
given as the cause for hospital admission) had a lower death rate than those with hospital-
acquired ARF 19.  
Long term outcome and quality of life in ICU survivors 
The long term survival of patients who after having been critically ill and 
recovered has been reported to be far more encouraging than the in hospital survival rates 
provided by most studies. In patients who have survived an episode of renal failure the 
need for post recovery renal replacement therapy has been quoted to be as high as 30%. 
In one particular study 118 the 6 month survival rate of patients who survived to hospital 
discharge was approximately 69% and the five year survival rate was 50%.  Seventy 
seven percent of the patients reported good to excellent health status in the above study. 
Another prospective study revealed six month survival rates of 73% 119. Literature on 
quality of life after therapy for ARF say that the health related quality of life (HRQL) 
may not be predictable from data available at the time of dialysis initiation in the above 
 52
study. In retrospect, surviving patients agree with the decision to accept dialysis, even 
when their HRQL is poor. 
 
In conclusion it is doubtful that we will ever have an epidemiologic 
surveillance system for ARF comparable to that provided for other infectious or 
multisystem disorders. Development of a rapid and sustained decrease in GFR, urine 
output, increase in serum creatinine from the baseline values and /or all the three 
parameters can be used as a definition for ARF. Current understanding of the 
epidemiology of ARF as per the available studies adds to the growing evidence that 
Acute Renal Failure is a major public health burden, taking its toll in morbidity, 
mortality, and cost, and justifies the call for additional research support to ultimately 
provide more effective preventive and therapeutic interventions.  
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MATERIALS AND METHODS 
 
The design of the study was a unicenter observational prospective cohort study. There 
was no intervention.  The duration of the study was a fixed six month period from 
February 2006 to July 2006 (6 months).  
 
Study population  
This study was conducted on all patients >14 years admitted to the surgical intensive care 
unit, fulfilling any one of the inclusion criteria for acute renal failure. The inclusion 
criteria that was used for this study is the RIFLE criteria for classifying Renal failure120. 
It is as follows.  
 
  
 
 
 
 
 
 
 
Patients were excluded from the study if  
a) Age was less than 14 years. 
b) Loss or End stage renal disease as defined by RIFLE. 
Category GFR Criteria Urine Output (UO) 
Criteria 
Risk Increased creatinine x1.5 or 
GFR decrease > 25% 
UO < 0.5ml/kg/h x 6 hr 
Injury Increased creatinine x2 or 
GFR decrease > 50%  
UO < 0.5ml/kg/h x 12 hr 
Failure Increase creatinine x3 or 
GFR decrease > 75% 
UO < 0.3ml/kg/h x 24 hr or 
Anuria x 12 hrs 
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Loss 
 
 
Persistent ARF = complete loss of kidney function > 4 weeks 
 
ESKD 
 
 
End Stage Kidney Disease (> 3 months)  
 
Sample size : 
As per the statisticians advice a defined period of study was chosen before 
the onset of study. This period was chosen as six months. All patients admitted under the 
surgical intensive care unit of this tertiary referral hospital would be screened with the 
RIFLE criteria and subsequently be included in the study.  
Patients fulfilling the criteria on admission as well as patients developing 
acute renal failure during the course of treatment for other illnesses in surgical ICU were 
included in the study. The day of admission into the study was considered the first day. 
All patients were included in the study based on the serum creatinine or the urine output 
components of the RIFLE criteria. Base line creatinine values for patients with no 
previous records and no history of preexisting renal disease were estimated using the 
simplified Modification of diet in renal disease (MDRD) formula. (appendix 1). 
Setting: The study was done in the surgical intensive are unit of a multi specialty tertiary 
care referral hospital. This ICU receives patients from all surgical specialties except 
cardiothoracic, pediatric and neurosurgical units. 
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Data collection  
Data collection included assessment of severity of illness by calculation of 
Acute Physiology and Chronic Health Evaluation (APACHE II) score and Sequential 
Organ Failure Assessment (SOFA) score at admission (Appendix 2,4,5and 6). The data 
collection also included daily values for serum creatinine, urine output, highest values for 
lactate and random blood sugar. 
There was no randomization of treatment options for the purpose of this 
study. All management decisions were made as per existing ICU protocol. The indication 
for RRT was decided in consultation with our team of nephrologists. Patients with ARF 
were screened for their diagnosis at the time of inclusion in to the study. If the diagnosis 
was changed during the course of the patient stay in surgical intensive care unit, the one 
thought to be leading to acute renal failure was considered to be the etiology. 
Definitions for sepsis, polytrauma , cardiovascular dysfunction, pulmonary dysfunction , 
hematological failure and hepatic failure are as per literary guidelines (appendix 7).  
Statistical analysis 
The SPSS 11.5 (Statistical package for social sciences Inc. Chicago, IL) was used. 
Continuous data are presented as mean and (standard deviations) and were analyzed with 
the T test. Comparisons between groups were done using analysis of variance test for 
numerical values and chi square test for comparing the proportions. An analysis of factors 
affecting the mortality was done with the above tests. The significant factors which were 
identified were then subjected to a logistic regression analysis with mortality as the 
dependant variable.  Continuous variables chosen for the logistic regression were then 
categorized. The odds ratio for acute physiological parameters in the first 24 hours of 
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ICU admission and causes of ICU admission were studied. In view of the smaller sample 
size logistic regression analysis was performed on fewer variables. The Calibration of the 
results of the logistic regression were assessed by goodness of fit from Hosmer 
lemeshow.  The Hosmer Lemeshow test compared model performance (observed versus 
expected) across the deciles of risk to test whether the model is biased (i.e performs 
differentially at the extremes of risk. A non significant value for this test suggests an 
absence of such bias.  
Receiver operating characteristic (ROC) curve is a graphical representation of the 
relationship between the sensitivity and the specificity of a particular test. The area under 
the curve (AUC) represents the overall accuracy of the test. The larger the area  the better 
is the test. The ROC curve was used to evaluate the APACHE II and the SOFA scores in 
this population.  
All p values less than 0.05 were considered significant in this study.  
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      RESULTS 
 
 
 
Incidence of ARF  
During the six month study period 422 patients were admitted to the 
surgical intensive care unit. Of these patients 97 met the RIFLE criteria for acute renal 
failure.  The calculated incidence of ARF is 22.7%. 
 
Demographic pattern of ARF  
Of the 97 patients diagnosed to have ARF, the distribution of patients 
across the deciles of age was a normal distribution, with a bulk of the patients falling in 
the 30 to 69 age group (Table–1). With respect to sex of the patient (Table-2), males had 
higher incidence 73.2% vs. 26.8%.  
 
Classification of ARF  
In this study, 47% of the patients with ARF belonged to the risk category, 
31% of the patients belonged to the injury category and 22 % belonged to the failure 
category. (Table-3). 
 
Etiology of ARF 
  The leading cause of ARF in the study cohort was sepsis. 55 of the 97 
patients were diagnosed with sepsis. The next most common cause of ARF was 
polytrauma(10%). ARF following post arrest sequelae was the etiology in 10% of the  
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Table 1 Demographic pattern in the study population  
                                                                                                       
 
       Table 2 
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           Table 3 : Frequency of acute renal failure based on the inclusion criteria 
 
 Frequency Percent
Male 71 73.2 
Female 26 26.8 
Total 97 100.0 
Inclusion criteria Frequency Percent 
 
Risk 
 
45 
 
47 
 
Injury 
 
32 
 
31 
 
Failure 
 
22 
 
22 
 
Total 
 
97 
 
100 
Scatter diagram showing a 
good age distribution of 
the study population            
Gender distribution  
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patients. Hepato renal syndrome and hemorrhagic shock caused ARF in 6 and 4 % of the 
patients respectively.( Table 4) 
 
Mortality in patients with ARF  
Of the 97 patients admitted with ARF the mortality rate was 47%(n=46). 
The leading cause of mortality was sepsis (Table 4). The case fatality rate for sepsis was 
62%. The combination of sepsis with ARF is associated with a high mortality in our 
study. Sepsis was found to be a significant cause of mortality (p<0.01).  Polytrauma was 
found to be a significant cause of mortality (p<0.05).  
 
Survival in the three groups  
  Of the 51 survivors in the study, 31 patients belonged to the risk group. 13 
patients belonged to the injury group and only 7 belonged to the failure group (Table 5). 
Among the non survivors the number of patients falling under the risk group was 14,  
under the injury group was 17, and  the failure group was 15.   
 
Prognostic   screening  
  The risk, injury and failure groups were compared with each using the 
APACHE II score, the APACHE predicted mortality, the APACHE adjusted mortality 
and the SOFA score (Table 6).   . 
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Table 4: Etiology of Acute Renal Failure and outcome 
   
 
                    Etiology 
 
Frequency 
 
Percent 
 
Mortality 
Case 
fatality  
 
P value 
 
Sepsis 
 
55 
 
56.7 
 
34/55 
 
62% 
 
<0.01 
 
Polytrauma 
 
10 
 
10.3 
 
1/10 
 
10% 
 
<0.05 
Crush syndrome  4 
 
4.1 
 
3/4 
 
75% 
 
NS 
Hepato renal syndrome  6 
 
6.2 
 
2/6 
 
33% 
 
NS 
Acute cardio-respiratory failure  10 
 
11 
 
5/10 
 
50% 
 
NS 
 
Major surgery 
 
6 
 
6.2 
 
0/6 
 
0% 
 
NS 
 
Obstructive renal failure 
 
1 
 
1.0 
 
0/1 
 
0% 
 
NS 
 
Renal parenchymal causes 
 
1 
 
1.0 
 
0/1 
 
0% 
 
NS 
 
Hemorrhagic shock 
 
4 
 
4.1 
 
1/4 
 
25% 
 
NS 
 
Total 
 
97 
 
100.0 
 
46/97 
 
47% 
 
NS 
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The  
 
 
APACHE II and the SOFA score showed a clear demarcation between the three groups. 
All mean values for the three groups were found to be lower for the risk and subsequently 
higher for the injury and failure groups. Analysis of variance for these factors was 
significant statistically (p<0.001).   
When these prognostic scores were applied to the survivors and non 
survivors we found significance between them for the APACHE and SOFA scores 
(p<0.001). (Table 6A). 
The mean age, number of days in ICU and the duration of mechanical ventilation was 
higher in the injury group as compared to the risk and failure groups. Statistical 
significance was lacking for the above factors (Table 6). Between the survivors and the 
non survivors there was a rise in the mean age, duration of ventilation and the duration of  
 
RISK 
 
INJURY 
 
FAILURE             SURVIVORS                      NON SURVIVORS 
 
           Table: 5 Inclusion Criteria Vs Outcome   
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Table 6: Prognostic screening for patients with Acute Renal Failure based on             
 
inclusion criteria 
 
 
Table 6 A : Prognostic screening for patients based on the outcome  
 
Inclusion 
criteria 
 
Age 
 (years) 
 
ICU 
days 
 
Mech. 
vent 
days 
 
APACHE 
II 
APACHE 
expected 
mortality 
(%) 
APACHE 
adjusted 
mortality 
(%) 
 
SOFA at 
admi 
ssion 
 
Risk 
(n=45) 
 
 
Mean 
(SD) 
 
45.27 
(15.9) 
 
4.51 
(4.12) 
 
3.84 
(4.21) 
 
16.73 
(6.261) 
 
28.20 
(17.43) 
 
30.28 
(21.87) 
 
6.71 
 
(3.1) 
 
Injury 
(n=30) 
 
 
Mean 
(SD) 
 
52.43 
(15.50) 
 
5.77 
(4.84) 
 
5.23 
(4.65) 
 
21.0 
(7.174) 
 
41.58 
(22.32) 
 
47.01 
(26.31) 
 
7.4 
(2.97) 
 
 
Failure 
(n=22) 
 
 
Mean 
(SD) 
 
47.0 
(15.75) 
 
 
4.59 
(3.81) 
 
4.64 
(3.76) 
 
24.64 
(3.995) 
 
52.77 
(12.24) 
 
65.31 
(11.59) 
 
11.4 
(3.13) 
 
P value  
 
0.156 
 
0.430 
 
0.378 
 
<0.001 
 
<0.001 
 
<0.001 
 
<0.001 
 
Outcome 
 
 
Age 
 
ICU 
days 
Mech. 
ventila
tion 
days 
 
 
APACHE 
II 
APACHE 
expected 
mortality 
(%) 
APACHE 
 adjusted  
mortality     
 
SOFA     
admission  
 
Survivo
rs 
(n=51) 
 
Mean 
SD 
 
43.96 
(16.26) 
 
3.47 
(3.28) 
 
3.84 
(4.21) 
 
15.57 
(4.993) 
 
24.74 
(13.118) 
 
26.29 
(17.974) 
     
     6.63 
(3.09) 
 
Non 
surv. 
(n=46) 
 
Mean 
SD 
  
52.26 
(14.49) 
 
 
5.54 
(4.94) 
 
5.23 
(4.65) 
 
24.65 
(5.372) 
 
52.51 
(17.152) 
 
62.37 
(18.282) 
   
   10.3 
(2.89) 
P  0.34 
 
0.41 
 
0.016 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
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stay in the ICU . There was significance between these two groups for mean duration of 
mechanical ventilation also (p=0.016).. (Table 6A) 
 
Physiological and biochemical variables: 
The lowest values for mean arterial pressures (p=0.002), lowest value for 
pH(p=0.040), and the highest value for serum creatinine(p=<0.001) (Table 7) were 
significantly different across the three groups. Similar trends are observed for urine 
output. The mean value of 24 hourly urine output in the failure group was significantly 
lower(p<0.001). There was no significance between the risk, injury and failure groups for 
central venous pressures, arterial lactate, bilirubin   and random  blood sugar on 
admission. (Table 7) 
  Values for mean arterial pressure and central venous pressures on 
admission were found to be lower in the non survivors, possibly indicating lower filling 
pressures and perfusion. Mean values for pH were also considerably lower for the non 
survivors (7.16) as compared to the survivors (7.29). (Table 7A) 
   
There is statistical   significance between the survivors and non survivors 
for values for mean arterial pressures (p=0.00), pH (p<0.001), 24 hourly urine output 
(p=0.00) and random blood sugar levels( p=0.001).There is no significance for admission 
creatinine, arterial lactate, bilirubin and central venous pressures between survivors and 
non survivors.  
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Table 7: Physiological  and biochemical variables for the three groups  
 
 
 
                  Table 7A: : Physiological  and biochemical variables and outcome                                            
           
Outcome 
variable 
MAP 
Adm 
(mm 
of hg) 
CVP 
Adm 
(cm 
of 
water)
 
pH 
adm 
 
 
Creat 
adm 
Blood 
Sugar 
Adm 
(mg%) 
 
Bilirubin 
values 
 
Lactate 
levels 
1st day 
urine 
output 
(litres) 
 
Survivors 
(n=51) 
 
Mean 
(SD) 
 
71.88 
(15.5) 
 
7.35 
(5.3) 
 
7.2922 
(.09) 
 
2.147 
(1.17)
 
150.80 
(66.63)
 
2.300 
(4.71) 
 
2.1 
(1.1) 
 
1.556 
(.5424) 
Non 
survivors 
(n=46) 
 
Mean 
(SD) 
 
 
59.11 
(15.7) 
 
6.74 
(4.3) 
 
7.1663 
(.092) 
 
2.457 
(1.16)
 
191.41 
(54.3) 
 
2.207 
(3.0) 
 
2.7 
(2.10) 
 
0.770 
(0.4776)
 
P value 
    
0.00 
 
0.54 
 
<0.001
 
0.196 
 
0.001 
 
0.909 
 
0.14 
 
0.00 
 
 
 
Inclusion 
criteria 
 
MAP 
(mm of 
hg) 
 
CVP 
(cm of 
water) 
 
 
pH 
 
 
Creat 
  mgm%
 
Blood 
Sugar 
(mg%) 
 
1st day urine 
output(l/day)
 
 
Risk 
(n=45) 
 
Mean 
(SD) 
 
71.67 
(16.37) 
 
 
7.11 
(3.45) 
 
7.254 
(0.040) 
 
1.6 
(0.25) 
 
170.6 
(72.50) 
 
1.496 
(0.586) 
 
Injury 
(n=30) 
 
Mean 
(SD) 
 
63.47 
(16.84) 
 
 
7.40 
(5.17) 
 
7.239 
(0.118) 
 
2.4 
(0.67) 
 
162.5 
(51.36) 
 
1.062 
(0.67) 
 
Failure 
(n=22) 
 
Mean 
(SD) 
 
57.09 
(13.56) 
 
 
8.11 
(5.35) 
 
7.180 
(0.127) 
 
3.5 
(1.75) 
 
179 
(63.07) 
 
0.765 
(0.424) 
 
P value  
 
0.002 
 
0.977 
 
0.040 
 
0.00 
 
0.657 
 
0.00 
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Outcome in terms of mortality is statistically significant between survivors and non 
survivors for the following   
• presence of cardiovascular failure (p<0.001), 
• respiratory failure (p=0.003),  
• hematological failure (p<0.001),  
• and presence of systemic infection at admission (p=0.006). 
• presence of diabetes mellitus (p=0.046).  
Emergency or elective nature of the surgery did not significantly affect 
mortality in this study.  
Intervention ;  
  The five variables in this data include use of diuretics, use of the drug N 
Acetyl cysteine, need for renal replacement therapy(RRT), use of ionotropes and need for 
mechanical ventilation. 
  Across all three groups we noticed a uniform pattern of increased usage of 
diuretics among the non survivors (Table 8). In this cohort 16 patients required RRT of 
whom 9 were in the failure group. The need for mechanical ventilation was also found to 
increase as we proceeded from the risk to the failure groups. There was statistical 
significance between the groups for use of diuretics and RRT. There was no significance 
for mechanical ventilation between the three groups. 
  Logistic regression analysis for predictors of mortality was done with 
parameters   and variables found to be significant by the earlier analysis. High blood 
sugar values >190 mg% (OR 8.58, 2.0-33.2, P value 0.003) and use of diuretics (OR 
5.20, CI 1.6- 23.3, P value 0.031) were found to associated with mortality. Hosmer and                  
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 Table 8: Intervention provided for the different groups 
 
 
Inclusion criteria  Diur 
etics 
Iono 
tropes 
   Use  
of NAC 
 
RRT 
Mech. 
 vent . 
Risk  Survivors   
n =31 
     
8 
 
18 
  
7 
          
0 
           
23 
Non survivors  
n =14 
     
10 
  
14 
 
4 
          
1 
          
12 
Injury  Survivors   
n=13 
     
6 
 
7 
 
4 
          
1 
          
11 
Non survivors  
n=17 
    
15 
           
17 
 
8  
          
5 
          
15 
Failure  Survivors   
n=7 
   
5 
 
5 
 
4 
          
2 
           
5 
Non survivors  
n=15 
   
13 
           
15 
 
 7 
          
7 
          
15 
      
P value  
   
<  0.01
         
0.20 
          
0.10 
        
0.001 
          
NS 
 
                  
                            Table 8A:  Intervention provided versus outcome 
                                            
 
                
 
 
 
 
Intervention survivors Non 
survivors
p value  
Use of diuretics 30/51 27/46 <0.001 
Use of NAC 15/51 19/46 0.220 
Use of ionotropes 30/51 46/46 <0.001 
Mechanical ventilation 39/51 46/46 0.001 
Emerg/ Elect surgery 35/12 38/6 0.281 
Need for RRT 3/51 13/46 0.003 
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lemeshow for goodness of fit test showed a  p value of 0.604 with an over all percentage 
of 77.3%.  
All 46 of the non survivors required ionotropes and mechanical 
ventilation.(Table 8A) Of the 16 patients in the whole study who required dialysis, 13 
were non survivors. There is an increases use of diuretics among the non survivors 
(27/46). The use of  diuretics, ionotropes, need for RRT, mechanical ventilation was 
significantly higher in the non survivors .  
    
 We studied the efficacy of the APACHE II and SOFA scores in the study 
population with the help of an receiver operating characteristic curve (ROC) curve. The 
ROC curve gives an estimate of the sensitivity and specificity of the test.  
At an APACHE II score of 19.5 the test was seen to show a sensitivity of 80% and a 
specifity of 78%. For SOFA at a value of 8.5 the test was 70%sensitve and 70%specific. 
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The area under the curve( AUC)  for the APACHE     0.890+/- 0.033 p value 0.000 
      
 The area under the curve( AUC)   SOFA                    0.801+/- 0.044 p value 0.000 
                                     
                                                               FIGURE 4 
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DISCUSSION  
 
 
 
In the critically ill population prevalence reported for ARF is in the range 
of 3% to 25%2,6,22,115. The greatest prevalence of ARF (24%) in the critically ill was 
quoted by Mendonca 2 et al, with renal failure due to surgical or trauma related illness 
accounting for one fourth the cases. Our study was done only in the surgical intensive 
care unit and the prevalence was found to be 22%. 
Prospective studies11 involving the RIFLE criteria show an incidence of 
ARF of 52% of patients.. The proportion of distribution of patients under the risk, injury 
and the failure groups  was – 49%,29% and 22% (Ahlstrom et al11 ), and– 32%, 30.6% 
and 23% (Obaseif et al 122). Our study done in the SICU shows an  incidence of 22%. The 
proportion of patients falling into the groups risk, injury and failure was 47%, 31% and 
22% respectively. 
ARF is found to be more common among the males. Studies by Mehta et 
al18, Sural et al17, Abosaif et al122 and Hoste et al22 quote percentages of 71%, 70%, 67% 
and 66% respectively, in favor of the males. In our study also we found that the incidence 
was higher amongst the males (73% versus 27%), but with no statistical significance for 
mortality. 
Uchino et al123 and Mendonca et al2  have found that increasing age was 
found to be significantly associated with mortality in patients with ARF.  In our study 
there was no significant relation between age , incidence of ARF, and mortality.  This 
could be because the bulk (table 1) of the patients who were admitted in this study were 
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between the 30 to 65 age group and the numbers above 65 were not significant enough to 
be compared. This is similar to findings of other studies122,22,17,18.  
The APACHE II scoring has been found to be reliable and  highly 
indicative of mortality rates.  Mehta et al18 others 11,122,22 all quote a higher APACHE 
score for patients with increasing severity of acute renal failure.     
In our study the mean values for APACHE II in the risk group was 16, for 
the injury group it was 21, and for the failure group it was 24 (Table 6). Ahlstrom et al11 
in their study quoted values of 16, 18 and 22 as the values for the respective groups. 
Abosaif 122 et al gave scores of 20, 22 and 26 for the mean values in the three groups 
respectively.. 
On comparison of the prognostic factors for mortality the APACHE II 
score with its predicted rates and adjusted rates was very discriminatory (Table 6A). The 
APACHE adjusted mortality rate was quite useful in this study given the fact that severity 
of the precipitating illness was given due importance while considering the outcome. 
  The SOFA score has been used by Mendonca et al 2 and the SAPS II score 
was used by Abosaif et al, and they too have found an important association in terms of 
mortality and higher admission scores. Flavio et al 124 in their prospective study showed 
that initial SOFA scores of 11 or more was indicative of 80%mortality prediction. This 
correlated well with the failure group and the non survivors  in our study (Table 6 and 
6A).  ROC curves for the APACHE and SOFA scores for predicting mortality showed 
values of 19.5 and 8.5 respectively(fig.4). 
The most common cause of ARF in this cohort of patients was found to be 
sepsis. Many studies reported on acute renal failure with a focus on sepsis. Hoste et al 22  
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found that the incidence of ARF in patients with sepsis was 16.2%. Rangel et al125 found 
an incidence of 19%, Brun et al 126 found an incidence of 21%. Schrier et al 23 found that 
the incidence of ARF increased to 23% and 51% with culture positive sepsis and septic 
shock respectively. Mortality rates with ARF complicating sepsis are between 50-70%127. 
Our study showed an incidence of sepsis with ARF of 56% and a fatality rate of 62%. 
In a large  multicentric study done by Metnitz et al 128 ARF due to 
polytrauma was seen in 11.7% of all critically ill patients. This study however included 
medical and surgical patients. Mendonca et al 2 in their study said that 9% of the ARF 
population was admitted following trauma. In our study polytrauma   and crush syndrome 
were found to be the cause of ARF in 10% and 4%of the patients respectively. 
Arabi et al 129 have shown an incidence of ARF in 44 % of critically ill 
patients with cirrhosis. None of the patients who developed hepato renal syndrome (HRS) 
in our study were thought to be cirrhotic. Two patients had jaundice complicating 
pregnancy, with the other four having liver failure due to cholecystitis or malignancy. 
The study was done in a surgical ICU and hence HRS following cirrhosis may not be 
present.  
Ten percent of patients developed ARF following cardio respiratory arrest. 
Mattana et al 130 showed that ARF in patients after cardio respiratory arrest has been 
shown to be associated with a high mortality of 93%. The mortality rate in our study in 
this subgroup is 50%. The other causes of ARF in our study were major surgery 6%, 
obstructive renal failure 1%, intrinsic causes 1%, and hemorrhagic shock 4%. These were 
not associated with mortality significantly.  
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The duration of stay in ICU was similar in all three groups and was not 
found to significantly affect outcome (Table6). 
  Factors leading to the outcome (etiology, clinical and biochemical 
parameters, and patient management.) in terms of mortality were analyzed by logistic 
regression. Physiological and biochemical parameters recoded on the first day varied 
significantly between the risk, injury and failure groups and were predictive of mortality 
following ARF. These results compare well with those of Hoste et al , Mehta et al and 
Abosaif et al. Through logistic regression we found that high random blood sugar levels 
at admission were associated with increased mortality.  
   Significance was found between the survivors and the non 
survivors for diuretics (p<0.001), ionotropes (p<0.001), mechanical ventilation 
(p=0.001),  and need for RRT (p=0.003. The need for ionotropes, mechanical ventilation 
and RRT have been shown to be significantly associated with mortality by Uchino et 
al123, and Lamiere and Hoste et al 22 . The sicker the patient the more was the use of 
ionotropes, mechanical ventilation and RRT.  
Logistic regression analysis showed that diuretic use was significantly 
associated with adverse outcomes in ARF.  This may be due to a direct deleterious effect 
of diuretic agents as suggested by Pascual 131 and Mehta, and Lamiere et al 132,or a  delay 
in the institution of RRT.  Data from a randomized, blinded clinical trial are not available 
as of now. More trials are needed to prove its benefit in ARF.  
Need for RRT was more in the non survivor(13 out of 46, p=0.003) and 
the failure groups( 9 out of 16, p=0.001) (Tables 8 and 8A). N Acetyl cysteine was used 
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based on individual clinicians judgment and was not found to alter outcome. A 
randomized, control trial is necessary to prove usefulness. 
Despite the fact that renal-replacement therapy has been available for 
decades, many patients have preexisting conditions that predispose them to acute renal 
failure and to concomitant extrarenal complications that cause multiorgan failure. 
Although there is a consensus that the need for RRT and the delivered dose of 
hemodialysis is related to morbidity and mortality, there is no consensus on the 
appropriate dose in patients with ARF. Conflicting data are available regarding the 
above114. The hypothesis that increasing use of RRT, and increasing the intensity of the 
delivered dose of hemodialysis in critically ill patients with acute renal failure reduces the 
rate of uremic complications and improves the outcome is logical, yet remains unproved, 
since it is based on scarce and conflicting data.  
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CONCLUSIONS  
This study identifies and describes the differences in clinical profile and 
outcome of patients diagnosed as Risk, Injury, or Failure under the RIFLE scoring for 
ARF. We found that ARF formed part of the clinical profile in 22% patients admitted in 
the surgical ICU over a period of six months. Mortality was 47% in those with ARF. 
Higher APACHE II scores, prolonged ventilation, lower mean arterial pressures at 
admission, lower arterial pH, lower urine output, and higher random blood sugars levels 
on admission were associated with higher mortality. The above results show that the 
RIFLE scoring was quite accurate with regard to identifying the sicker patients among 
the study population. 
We conclude that  
1.   The RIFLE score is a good assessment of the incidence of ARF in the critically ill 
population. Each subsequent stage of ARF showed greater mortality than the previous 
stage.  
2.  The admission APACHE II and the admission SOFA score were equally good in the  
predicting the outcome of patients with ARF . 
3.    Sepsis was associated with the highest incidence of ARF. Cardiovascular, respiratory 
and hematological system failure at admission, presence of systemic infection at 
admission, use of diuretics and ionotropes, need for renal replacement therapy, and 
mechanical ventilation were found to be significantly associated with adverse outcome in 
ARF. 
4.   Early institution of RRT could help in improving patients in the injury and failure 
groups. 
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5.  By using the RIFLE score the early recognition of the risk group is possible and 
intervention could prevent risk from progressing to failure. 
6.  Further randomized studies are needed to prove the influence of factors such as 
diuretics, RRT and Nacetyl cysteine . 
 
 
. 
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Appendix 1  
 
 
 
 
 
Appendix 2 : SOFA(Sequential Organ Failure Assessment) Score124 
 
 
 
 
 
 
 
 Simplified MDRD (Modification of diet in renal disease)120 formula for estimation  of 
baseline creatinine  
 
Age 
(years) 
Black males (mg/dl 
[μmol/l]) 
Other males (mg/dl 
[μmol/l])
Black females 
(mg/dl [μmol/l])
Other females 
(mg/dl [μmol/l])
 
20–24 1.5 (133) 1.3 (115) 1.2 (106) 1.0 (88) 
25–29 1.5 (133) 1.2 (106) 1.1 (97) 1.0 (88) 
30–39 1.4 (124) 1.2 (106) 1.1 (97) 0.9 (80) 
40–54 1.3 (115) 1.1 (97) 1.0 (88) 0.9 (80) 
55–65 1.3 (115) 1.1 (97) 1.0 (88) 0.8 (71) 
>65 1.2 (106) 1.0 (88) 0.9 (80) 0.8 (71) 
 
SOFA score  0 1 2 3 4 
Respiration  
PaO2/ FIO2 
(mm of hg) 
 
>400 
 
301-400 
 
201-300 
 
101-200 
 
<=100 
Coagulation 
Platelets (x 103) 
>150 101-150 51-100 21-50 <20 
Liver  
Bilirubin( mg%) 
<1.2 1.2-1.9 2.0-5.9 6.0-11.9 >12.0 
Cardiovascular  
Hypotension 
No 
hypotension  
MAP<70 
mm hg 
Dopamine<5
mcg/kg/min 
or 
Dobutamine 
(any dose ) 
Dopamine 
>5 
mcg/kg/min 
Dopamine 
>15 
mcg/kg/min 
CNS  (GCS) 15 13-14 10-12 6-9 <6 
Renal  
Creatinine (mg%) 
Urine output  
 
<1.2 
 
 
 
1.2-1.9 
 
2.0-3.4 
 
3.5-4.9 
<500 ml/day 
 
>5.0 
<200 ml/day 
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Appendix 3                                                           
ARF STUDY PROFORMA 
 
Serial no 
 
Name :                         sex  M/F       Age :  
Date of admission into ICU                                   Date of Discharge from ICU     
Diagnosis 
 
Inclusion criteria         RISK            Rise in serum creatinine by 1.5 times  
             Urine output<0.5 ml/kg/hr for 6 hours 
             OR  
INJURY       Rise in serum creatinine by 2 times  
             Urine output<0.5 ml/kg/hr for12 hours 
       OR  
                    FAILURE     Rise in serum creatinine by 3 times 
      Serum creatinine >4 mg% and acute rise in serum                 
creatinine by more than 0.5% 
             Urine output<0.3 ml/kg/hr for 6 hours 
Pre morbid creatinine: if known:                             
Number of Ventilator days:                                     Infection at admission: yes/no 
Organ system failure:      
CVS yes/no RS yes/no Hematological yes/no CNS yes/no Liver yes/no
    
APACHE II ( worst score in the first 24 hours) (A) 
Temp  MAP HR RR AaO2/PaO2 GCS 
 
pH PCV TC Na K Creat
            
Age Score (B) APACHE Predicted Mortality rate                  % 
Chronic health point score (C) APACHE Adjusted Mortality rate                    % 
Total score   APACHE = A+B+C=  
SOFA ( worst score in the first 24 hours)                                                       Total SOFA =  
Respiration  Coagulation CVS Hematological CNS Hepatic  
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Physiological  Day 1 Day2 Day3 Day4 Day5 Day6 Day7 
Heart rate         
Resp rate         
MAP        
CVP        
Temp         
Urine output         
GCS        
                                                                       Lab values 
Blood sugar        
Lactate         
PaO2        
FiO2        
PaCO2        
pH        
Platelet         
Creatinine         
Bilirubin         
Na        
K        
Total WBC         
PCV        
                                                                    Intervention  
Diuretics         
N Acetyl 
Cysteine  
       
Ionotropes        
Mechanical 
ventilation  
       
RRT        
 
Number of surgeries:  
Emergency/ Elective surgeries: 
Pre existing chronic diseases : 
         
Outcome : Survivor / Non survivor 
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Appendix 4 
APACHE II SCORING . TOTAL SCORE = A+B+C 
Table A 
 
Table B: Age Points      
 
 
   Ref :                       critical  care medicine 1985;13;818-829. 
Physiological variable +4 +3 +2 +1 0 +1 +2 +3 +4
Temperature () > 41 39-40.9   38.5-38.9 36-38.4 34-35.9 32-33.9 30-31.9 < 29.9
Mean arterial pressure 
(mmHg) 
> 160 130-159 110-129   70-109   50-69   < 49
Heart rate (ventricular 
response) 
> 180 140-179 110-139   70-109   55-69 40-54 < 39
Respiratory rate (non-vetilated 
or ventilated) 
> 50 35-49   25-34 12-24 10-11 6-9   < 5
Oxygenation: AaDO2 or PaO2 
(mmHg)(FiO2 > 0.5 record 
AaDO2, FiO2 <0.5 record PaO2) 
> 500 350-499 200-349   <200 PaO2 
>70 
 
PaO2 
61-70 
  PaO2  
55-60 
 
PaO2 
<55 
Arterial pH > 7.7 7.6-7.69   7.5-7.59 7.33-7.49   7.25-7.32 7.15-7.24 <7.15
Serum sodium (mmol/l) > 180 160-179 155-159 150-154 130-149   120-129 111-119 < 110
Serum potassium (mmol/l) > 7 6-6.9   5.5-5.9 3.5-5.4 3-3.4 2.5-2.9   < 2.5
Serum creatinine (mg/dl) 
(double point score for acute 
renal failure) 
> 3.5 2-3.4 1.5-1.9   0.6-1.4   <0.6     
Hematocrit (% ) > 60   50-59.9 46-49.9 30-45.9   20-29.9   <20
W.B.C. (´ 102/mm3) > 40   20-39.9 15-19.9 3-14.9   1-2.9   <1
Glasgow coma score (GCS)  
Score =15- actual GCS 
                  
Serum HCO3 (venous-mmol/l) 
(not preferred, use if no ABGs) 
> 52 41-51.9   32-40.9 22-31.9   18-21.9 15-17.9 <15
Age < 44 45 ~ 54 55 ~ 64 65 ~ 74 > 75 
Score 0 2 3 5 6 
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TABLE C: Chronic Health Points (CHP) 
1. Assigned if the patient has a history of severe organ system insufficiency or is 
immunocompromised. 
2. For non-operative or emergency post-operative patients, 5 points; and for elective 
post-operative patients, 2 points.  
3. Organ insufficiency or an immunocompromised state must have been evident 
before hospital admission and must conform to the following criteria: Liver: 
biopsy proven cirrhosis and documented portal hypertension, episodes of past 
upper gastrointestinal bleeding attributed to portal hypertension, or prior episodes 
of hepatic failure/encephalopathy/coma. Cardiovascular: New York Heart 
Association Class IV (i.e. symptoms of angina or cardiac insufficiency at rest or 
during minimal exertion).Respiratory: chronic restrictive, obstructive, or vascular 
disease resulting in severe exercise restriction, i.e. Unable to climb stairs or 
perform household duties, or documented chronic hypoxia, hypercapnia, 
secondary polycythemia, severe pulmonary hypertension (>40 mmHg), or 
respirator dependency.Renal: receiving chronic dialysis. Immunocompromised: 
the patient has received therapy that suppress resistance to infection, e.g. 
immunosuppression, chemotherapy, radiation, long term or recent high dose 
steroids, or has a disease that is sufficiently advanced to suppress resistance to 
infection, e.g. Leukemia lymphoma, AIDS.  
 
                                                 APPENDIX 5  
                                    APACHE II expected mortality  
0-4 = 4% death rate  10-14 = 15% death rate   20-24 = 40% death rate 30-34 = 75% death rate 
5-9 = 8% death rate 15-19= 25% death rate   25-29 = 55%death rate  >34 = 85% death rate  
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APPENDIX 6                 APACHE ADJUSTED DEATH RATE 
Adjusted death rate
 
0  
Logit = -3,517+( Apache II) * 0,146 + Diagnostic category weight
Predicted Death Rate =eLogit/(1+eLogit) 
Diagnostic category weight (y)= 0  (a point for decimals)  
Nonoperative y Postoperative patients y y (if emergency)
Respiratory failure or insufficiency 
from: Multiple trauma 
-
1.684 -1.081 
Asthma / allergy -2.108
Admission due to 
chronic cardiovascular 
disease 
-
1.376 -0.773 
COPD -0.367 Peripheral vascular surgery 
-
1.315 -0.712 
Pulmonary edema 
(noncardiogenic) -0.251 Heart valve surgery 
-
1.261 -0.658 
Postrespiratory arrest -0.168 Craniotomy for neoplasm 
-
1.245 -0.642 
Aspiration / poisoning / Toxic -0.142 Renal surgery for neoplasm 
-
1.204 -0.601 
Pulmonary embolus -0.128 Renal Transplant -1.042 -0.439 
Infection 0 Head trauma -0.955 -0.352 
Neoplasm 0.891 Thoracic surgery for neoplasm 
-
0.802 -0.199 
Cardiovascular failure or insufficiency 
from : 
Craniotomy for ICH/ 
SDH/ SAH 
-
0.788 -0.185 
Hypertension -1.798 Laminectomy and other spinal cord surgery 
-
0.699 -0.096 
Rythm disturbance -1.368 Hemorrhagic shock -0.682 -0.079 
Congestive heart failure. -0.424 GI Bleeding -0.617 -0.014 
Hemorrhagic shock / 
hypovolemia 0.493 GI surgery for neoplasm 
-
0.248 0.355 
Coronary artery disease -0.191 Respiratory insufficiency -0.140 0.463 
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Sepsis 0.113 GI perforation / obstruction 0.060 0.663 
Post cardiac arrest 0.393
If not in one of the above, which major vital 
organ system led to ICU admission post 
surgery 
Cardiogenic shock -0.259 Neurologic -1.150 -0.574 
Dissecting thoracic / abdominal 
aneurysm 0.731 Cardiovascular 
-
0.797 -0.194 
Trauma Respiratory -0.610 -0.007 
Multiple trauma - 1.228 Gastro-intestinal -0.613 -0.01 
Head injury -0.517 Metabolic / renal -0.196 0.407 
Neurologic    
Seizure disorder -0.584    
ICH/ SDH/ SAH 0.723    
Other    
Drug overdose -3.353    
Diabetic ketoacidosis -1.507    
GI Bleeding 0.334    
If not in one of the groups above, 
which major organ system was the 
principal reason for admission: 
   
Metabolic / renal -0.885    
Respiratory -0.890    
Neurologic -0.759    
Cardiovascular 0.470    
Gastrointestinal 0.501    
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     APPENDIX 7 
Sepsis 23 was defined as evidence of serious bacterial infection in which two or more of 
the following were present. Proven or suspected microbial etiology with features of SIRS 
such as   
• Core body temperature >38 or <36 0 C,  
• Heart rate more than 90/Min,  
• Respiratory rate more than 20, or PaCO2 <32 mm of hg or need for mechanical 
ventilation,  
• White blood cell count >12 000 cells per mm3  or < 4000 /mm3 with more than 
10%band forms   
Polytrauma was defined as either an unstable pelvic fracture requiring more than 6 units 
of whole blood or packed red cells, or presence of two or more long bone fractures , or 
presence of a  pelvic fracture with long bone fracture and  a hollow viscus injury 121 . 
Cardiovascular dysfunction  was defined as a need for vasoactive medication, despite 
adequate filling up of the intravascular volume based on the central venous pressures.   
Pulmonary dysfunction was defined as need for mechanical ventilation.  
Hematological failure when the Platelet count were less than 100,000/mm3 . 
Liver dysfunction was defined with bilirubin levels greater than 2mg%. Patients with 
pre existing chronic liver disease were screened for a rise in bilurubin levels before 
defining them.Use of diuretics was defined as administration of either bolus doses or 
continuous infusion of diuretics. 
Systemic Infection at admission was defined as  
• fever ( > 38 °C) with or without chills.  
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• hypotension (systolic pressure <= 90 mm Hg) 
• With or without positive blood cultures 
• Appropriate antibiotic therapy being initiated on admission by the clinician  
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                                                              APPENDIX 8  
Coding for master sheet 
 
A    Hospital number  
B    Age  
C - Sex 0-male,1- female 
D-  Number of hospital days 
E    Number of ICU days 
F-   Inclusion criteria -       1 - risk, 2 - injury, 3-  failure 
G    Mortality 1-yes, 0- no 
H – APACHE  
I –  APACHE predicted mortality 
J -  APACHE adjusted mortality 
L – DIAGNOSIS Sepsis - 1, Trauma- 2, crush syndrome-3, hepato renal syndrome-
4,acute cardiogenic failure - 5, major surgery- 6, obstructive renal faliure- 7, renal 
parenchymal causes- 8 ,acute respiratory failure- 9, pancreatitis 10, -hemorrhagic shock 
11 
M- Organ failure  0-nil,1- one organ failure,2 two organ failure, 3- three organ failure, 4   
four organ failure, 5 five organ failure 
N-  CVS failure 1- yes, 0 – no 
O- Respiratory failure  1 - yes , 0- no 
P - Hematological failure 1 -yes, 0- no 
Q - Hepatic failure 1 -yes, 0- no 
R – CNS failure 1 - yes, 0- no 
S – Pre morbid creat 1- normal, 2 abnormal, 3 not known 
T    Bilirubin 
U- Infection at admission 1- Yes, 0- no 
V – Major surgery 1-yes, 0 - no 
W  systems involvement before arf  0 - nil,1- one system, 2- two system, 3- three 
system,4- four system, 5- five system 
X   systems involvement after  arf   0 - nil,1- one system, 2- two system, 3- three 
system,4- four system, 5- five system 
Y – Duration of ICU stay in days before inclusion into study  
Z- pre existing chronic illness 1yes, 0- no 
AA- Type of chronic disease     0- nil,1- diabetes mellitus,2- malignancy,3- ischemic 
heart/rhythm disorders, 4- urological disease, 5 chronic liver disease,6 - hypertension, 7- 
chronic respiratory failure ,8 pancreatitis 9- malignancy,10-  combination of 2 system 
disorders,11- combinanation  of three system disorders 
AB- use of diuretics 
AC - use of acetyl cysteine - 1- yes, 0- no 
AD - use of ionotropes  1- yes, 0- no 
AE mechanical ventilation 1- yes, 0- no 
AF mean arterial pressure at admission 
AG  CVP at admission 
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AH SOFA at admission 
AI  pH at admission  
AJ – lactate at admission 
AK – admission creatinine  
AL – blood sugar at admission 
AM admission urine  
AN  renal replacement therapy 1 –yes, 0 no 
AO  indication for renal replacement- 0 nil, 1-hyperalemia,2- severemetabolic acidosis, 3 
fluid overload, 4  rising creatinine, 5 oliguria 
AP     Nno of sittings of dialysis 
AQ – Number of surgeries 
AR - Ttype of surgery- 0  -no surgery , 1- emergency, 2 -elective 
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hospital nu age sexhos icu incmoapa apaap avendiagorgcv reshe he cnsprebiliruinfemasyssy icu tpretypeususeuse 
832742C 29 0 20 9 2 0 14 19 16 8 1 5 1 1 1 1 0 3 19 1 0 3 1 0 0 0 1 0 1
831367c 75 0 22 12 2 0 20 36 31 12 1 4 0 1 1 1 0 3 6.7 1 0 3 0 0 0 0 1 0 1
831565c 60 0 14 3 1 0 18 29 18 0 8 2 0 1 0 0 0 3 1.7 0 1 1 0 0 1 8 0 0 0
804174c 40 0 25 11 1 0 11 12 13 9 1 4 1 1 0 1 0 3 2.4 1 1 2 1 0 0 0 1 0 1
804052c 27 0 13 8 1 0 20 35 16 8 2 3 1 1 0 0 0 3 1 0 1 2 0 0 0 0 0 0 1
802285c 33 0 19 1 1 0 22 42 54 0 9 1 0 0 0 0 0 1 0.5 1 1 0 0 0 1 8 0 0 0
789426c 45 0 7 2 1 0 15 21 7 0 2 1 0 0 0 0 0 1 1 0 0 0 0 0 1 6 0 0 0
937227B 52 0 71 4 1 0 19 32 41 2 1 4 1 1 1 0 0 1 0.4 1 0 2 0 0 1 9 0 0 1
227995C 21 1 31 8 3 0 21 42 58 7 1 4 1 1 1 0 0 1 0.8 1 1 2 2 0 0 0 1 0 1
815843C 28 0 28 4 2 0 17 26 40 0 1 2 1 0 0 0 0 1 0.4 1 0 1 0 0 0 0 0 0 1
807315C 25 1 22 11 1 0 23 46 43 8 11 5 1 1 1 0 0 1 0.7 1 1 3 0 0 0 0 0 0 1
789111C 22 1 7 1 1 0 19 32 30 1 11 3 1 0 1 0 0 1 2.9 0 1 1 1 0 0 0 0 0 0
767280C 47 0 19 1 1 0 12 12 4 1 6 1 0 0 0 0 0 1 0.9 0 1 0 0 0 1 3 1 0 0
780728c 15 1 12 3 1 0 14 18 26 1 9 2 0 1 0 0 0 1 0.6 1 1 1 0 0 1 4 0 1 0
717285c 28 0 36 1 1 0 16 23 11 1 6 1 0 0 0 0 0 1 0.6 0 1 0 0 0 1 5 0 0 0
214768A 76 0 5 2 1 0 28 63 63 0 1 2 1 0 0 0 0 1 1 0 0 1 0 0 1 4 1 0 1
824533C 51 0 7 2 1 0 10 11 4 1 2 1 0 0 0 0 0 3 1 0 1 0 0 0 1 6 0 0 0
812288C 60 0 25 1 2 0 18 29 9 0 6 1 0 0 0 0 0 2 1 0 1 0 0 0 1 11 0 0 0
818657C 66 0 11 6 2 0 22 42 58 6 9 2 0 1 0 0 0 3 0.8 0 1 1 0 0 1 10 1 0 0
810383c 69 0 24 7 1 0 20 36 14 6 6 3 1 1 0 0 0 1 0.5 0 1 0 2 0 1 4 1 0 1
824752C 44 1 28 2 2 0 17 26 22 2 5 2 1 0 0 0 0 1 1 0 1 1 0 0 1 3 0 0 0
802327C 65 1 12 6 1 0 16 23 37 5 3 2 0 1 0 0 0 1 1 0 1 0 1 0 1 10 1 0 0
839468C 47 0 10 1 1 0 10 11 3 1 6 1 0 0 0 0 0 1 1 0 1 0 0 0 1 6 0 0 0
839487C 65 0 7 2 1 0 15 21 10 0 2 2 0 1 0 0 0 3 0.9 0 0 1 0 0 1 10 0 0 0
846244C 58 0 8 3 1 0 13 17 28 3 1 2 1 0 0 0 0 1 1 1 1 1 0 0 0 0 1 1 1
832528C 85 0 17 1 3 0 18 46 62 0 7 1 0 0 0 0 0 1 1 0 1 0 0 0 1 6 0 0 0
775245C 60 1 15 2 1 0 9 10 18 2 6 1 0 0 0 0 0 1 0.6 0 1 0 0 0 1 6 0 1 1
552686c 45 1 9 3 3 0 21 39 55 3 1 4 1 1 1 0 0 3 0.8 1 1 2 0 0 0 0 1 1 1
830061C 45 0 7 2 2 0 14 19 31 2 1 2 1 0 0 0 0 3 0.6 1 1 1 0 0 0 0 0 1 1
860605C 26 0 40 9 2 0 10 11 8 9 2 3 1 0 0 0 1 1 0.7 0 1 2 0 0 0 0 1 0 1
856330C 37 1 5 2 1 0 14 19 31 1 11 2 1 0 0 0 0 3 0.6 0 1 1 0 0 0 0 0 0 1
827396C 43 1 30 7 2 0 15 21 28 7 1 3 1 1 0 0 0 1 2.3 1 1 2 0 0 1 6 1 1 1
360605C 48 0 10 5 2 0 12 15 21 3 1 3 1 1 0 0 0 3 0.8 1 1 2 0 0 1 1 1 0 0
801557C 23 1 70 1 2 0 9 10 11 1 4 5 1 1 1 1 1 3 1.1 1 0 3 1 0 0 0 0 0 0
789770C 34 0 10 4 1 0 10 11 10 2 2 1 0 0 0 0 0 3 0.8 1 0 1 0 0 1 9 1 1 1
298849C 23 1 8 1 1 0 11 13 13 0 4 2 0 0 1 0 0 1 13 0 0 1 0 0 0 0 0 0 0
789197c 32 0 14 3 1 0 5 6 11 3 1 2 1 1 0 0 0 3 1.8 1 1 1 1 0 0 0 0 0 1
699898a 45 0 21 2 2 0 16 24 38 2 1 3 1 1 0 0 0 3 0.8 1 1 0 0 0 1 6 0 1 1
789949c 44 0 33 6 1 0 18 29 12 5 2 2 1 0 1 0 0 1 0.9 0 1 2 0 0 0 0 1 0 1
756819c 44 0 41 2 1 0 12 14 12 2 1 3 1 0 1 0 0 1 1.1 1 1 2 0 0 1 10 0 1 1
780072b 60 0 20 8 3 0 23 46 58 7 1 3 1 1 0 0 0 3 0.7 1 1 2 0 0 1 10 1 1 1
834535c 47 1 12 5 1 0 15 21 21 4 1 3 1 1 0 0 0 1 1.1 1 1 2 1 0 0 0 0 1 1
832924c 52 1 20 1 3 0 21 38 41 0 4 3 1 0 0 1 0 1 27 1 0 1 1 0 1 6 0 0 0
196173C 27 0 20 6 1 0 17 26 23 6 1 3 1 1 0 0 0 3 0.9 1 1 2 0 0 0 0 0 1 1
846162C 31 0 43 2 1 0 4 5 3 2 2 2 1 0 0 0 0 1 0.8 0 1 1 0 0 0 0 0 0 1
839476C 23 0 11 2 1 0 11 13 19 1 9 2 0 1 0 0 0 1 0.9 0 1 1 0 0 0 0 0 0 0
845811C 55 0 19 6 3 0 19 32 48 5 1 3 1 1 0 0 0 1 1 1 1 1 1 0 1 1 1 1 1
839188C 50 0 7 5 2 0 12 14 6 4 2 3 1 1 0 0 0 1 0.6 0 1 2 0 0 1 6 0 1 0
828232C 35 0 9 4 1 0 11 13 19 4 1 2 0 1 0 0 0 1 0.4 0 1 2 0 0 0 0 0 0 1
571893C 34 0 40 10 3 0 24 49 59 10 4 5 1 1 1 1 0 1 7 0 1 3 1 0 0 0 1 1 1
820021C 46 1 28 11 1 0 13 17 28 10 1 3 1 1 0 0 0 1 1.9 1 1 1 1 0 1 1 0 0 1
818563C 34 0 3 2 1 1 19 32 32 2 2 3 1 1 0 0 0 3 1 0 1 2 0 0 0 0 1 0 1
767691A 75 1 3 3 2 1 32 76 82 3 1 3 1 1 0 0 0 1 0.9 1 1 2 0 0 1 10 1 0 1
823419C 62 1 38 24 2 1 19 32 41 22 1 4 1 1 1 0 0 1 1.8 1 1 2 1 13 1 8 1 0 1
851199C 39 0 2 1 3 1 23 46 62 1 1 5 1 1 1 1 1 3 3.5 1 1 3 2 0 0 0 1 0 1
790386C 37 0 6 4 2 1 32 76 78 3 1 3 1 1 0 1 0 2 1.5 1 1 2 0 0 1 5 1 0 1
804486C 47 0 4 4 3 1 33 78 87 4 1 4 1 1 1 0 0 3 1.1 1 1 2 1 0 0 0 0 1 1
831974C 36 0 5 3 3 1 25 53 63 5 1 3 1 1 0 0 0 1 1 1 1 2 1 0 0 0 1 1 1
804248C 37 0 20 11 2 1 21 39 49 9 3 3 1 0 1 0 0 1 1.3 0 1 1 1 0 1 1 1 1 1
433307B 67 0 7 4 3 1 27 61 75 4 1 3 1 0 1 0 0 3 0.9 1 1 1 1 0 0 0 1 0 1
789407C 56 0 1 1 3 1 34 81 89 1 1 4 1 1 1 0 0 1 1.6 1 1 2 1 0 0 0 1 1 1
837723C 48 0 46 2 1 1 13 17 17 1 5 2 1 0 0 0 0 1 1 0 0 1 0 0 1 3 0 0 1
777323C 39 0 4 1 1 1 31 73 80 1 5 2 1 0 0 0 0 3 0.6 0 0 1 0 0 0 0 0 0 1
784850C 53 0 16 9 2 1 15 21 18 9 1 4 1 1 0 1 0 1 1.8 0 1 2 1 5 1 6 1 1 1
814614C 36 1 7 4 1 1 20 36 37 5 1 3 1 1 0 0 0 1 0.6 0 1 2 0 5 1 5 1 1 1
789083C 37 0 2 2 3 1 23 46 62 3 11 2 1 0 0 0 0 3 1 0 1 1 0 0 0 0 1 0 1
753790C 65 1 15 6 2 1 19 49 48 6 1 4 1 1 1 0 0 3 0.9 1 0 2 1 0 1 1 1 1 1
087763B 65 0 4 4 1 1 25 53 69 4 1 4 1 1 1 0 0 3 0.7 1 1 2 1 0 1 1 1 1 1
839241C 52 0 3 3 1 1 18 29 44 3 1 4 1 1 1 1 0 3 3 1 1 2 2 0 1 1 0 0 1
814833C 56 0 13 11 2 1 29 67 75 10 1 4 1 1 1 0 0 1 0.6 0 1 2 1 10 1 6 1 1 1
840506C 39 0 2 2 1 1 19 32 48 2 1 4 1 1 1 1 0 3 2.2 1 1 2 1 0 0 0 0 0 1
818562C 37 0 9 8 3 1 23 48 62 8 1 5 1 1 1 1 0 3 3.6 1 1 3 1 0 0 0 1 1 1
822215C 55 0 12 7 2 1 25 54 63 7 4 4 1 1 0 1 0 1 11 1 1 2 1 0 1 1 1 1 1
789175C 34 0 2 2 2 1 28 64 74 2 1 4 1 1 1 1 0 3 2.6 1 1 2 2 0 1 8 1 0 1
714553C 71 1 2 2 1 1 28 64 78 2 5 4 1 1 1 0 0 3 0.9 1 1 2 1 0 1 3 1 0 1
368098C 63 0 7 2 2 1 31 73 84 2 1 4 1 1 1 0 0 3 0.5 1 1 2 1 0 1 2 0 0 1
789200C 39 1 10 2 3 1 23 56 72 6 1 4 1 1 1 1 0 1 2.1 1 1 3 1 0 0 0 1 1 1
700835A 82 0 1 1 2 1 30 70 78 1 5 3 1 1 0 0 0 1 0.5 0 0 1 0 0 1 7 0 0 1
571893C 55 0 48 1 2 1 23 46 59 1 4 2 0 0 0 1 0 1 19 0 0 1 0 0 1 5 1 0 1
169695C 48 1 6 2 3 1 27 61 71 1 5 3 1 1 0 0 0 1 2.7 1 1 1 1 0 1 5 1 0 1
714553B 71 1 2 2 1 1 23 46 62 2 1 2 1 0 0 0 0 3 0.8 1 1 1 0 0 1 10 1 0 1
832557C 52 0 23 15 3 1 28 64 73 15 3 4 1 1 1 0 0 1 0.4 0 1 0 3 0 1 1 1 1 1
4470 74 0 10 10 3 1 28 64 78 10 1 4 1 1 1 0 0 1 0.7 1 1 2 1 0 1 10 1 1 1
818518C 69 0 21 4 2 1 34 81 89 3 1 5 1 1 1 1 0 1 6.6 1 1 2 2 0 1 10 1 1 1
823581C 40 0 9 2 3 1 25 50 66 5 1 4 1 1 1 0 0 1 2 1 1 2 1 0 0 0 1 0 1
828264C 38 0 3 3 3 1 28 63 78 3 1 3 1 1 1 0 0 3 5 1 1 2 1 0 0 0 0 0 1
832988C 19 0 1 1 3 1 23 46 56 1 1 4 1 1 1 0 0 3 1.5 1 1 2 2 0 0 0 1 0 1
833062C 58 1 11 5 2 1 28 64 74 5 1 4 1 1 1 0 0 1 1.7 1 1 2 2 0 1 1 1 1 1
800100C 55 0 9 6 3 1 25 53 63 3 3 2 1 0 0 0 0 3 0.9 1 1 1 0 0 1 1 1 0 1
817095C 63 0 11 9 2 1 20 35 45 9 1 3 1 1 0 0 0 1 1.9 1 1 1 1 7 1 10 1 1 1
480352B 66 1 7 7 1 1 25 53 56 7 1 3 1 1 0 0 0 1 1 1 1 1 1 0 1 1 1 0 1
789332C 61 0 8 8 2 1 24 50 61 8 1 3 1 1 0 0 0 3 0.9 1 1 1 1 0 1 10 1 0 1
846193C 51 0 19 19 1 1 17 26 41 19 1 4 1 1 1 0 0 1 1.5 1 1 2 1 9 1 1 1 1 1
426783B 61 0 18 8 1 1 28 63 73 8 1 4 1 1 1 0 0 1 1.2 1 1 2 1 0 1 6 1 0 1
774355C 67 0 39 13 1 1 25 53 62 13 1 4 1 1 1 0 0 1 0.8 1 1 2 1 0 1 2 1 0 1
454868C 66 1 1 1 2 1 27 60 74 1 1 3 1 1 1 0 0 1 1.3 1 1 2 1 0 1 1 1 0 1
804213C 29 0 15 15 1 1 11 13 22 15 1 4 1 1 0 1 0 1 4.1 1 1 3 1 0 0 0 1 1 1
memeanCVPsofa admisslactatadmadm.Adm renaindicno onumtype of surgery 
1 53 2 11 7.26 3 1.9 216 2.8 0 0 0 1 0
1 90 13 11 7.41 14 3.8 132 2.3 0 0 0 3 1
0 93 12 7 7.34 0.6 2.1 94 2.5 0 0 0 1 2
1 53 12 12 7.16 2.4 1.4 141 1.7 0 0 0 1 1
1 40 2 8 6.98 9 1.6 136 2.3 0 0 0 2 1
0 83 0 4 7.25 2 2.2 159 1.9 0 0 0 1 1
0 110 8 4 7.32 1.9 1.9 129 1.6 0 0 0 0 0
1 53 3 5 7.23 1.7 1.7 493 1 0 0 0 1 2
1 53 6 10 7.45 7 3.6 130 0.6 1 5 9 1 2
0 67 7 7 7.36 3 1.7 114 1.4 0 0 0 2 2
1 57 6 10 7.26 2.4 1.5 164 2.6 0 0 0 2 1
1 63 10 9 7.27 2.1 1.8 130 1.4 0 0 0 0 1
1 77 12 2 7.37 1.4 1.5 129 1.4 0 0 0 0 1
1 57 0 3 7.05 5 1.4 229 1.5 0 0 0 1 2
1 57 2 1 7.2 6.3 1.6 129 1.7 0 0 0 1 2
0 70 3 6 7.28 1.9 1.6 191 1.6 0 0 0 1 2
0 83 6 3 7.31 1.9 1.5 150 0.8 0 0 0 1 1
0 83 6 5 7.36 1.1 4 105 1 0 0 0 1 2
1 83 13 6 7.25 1.4 3.4 156 1.6 0 0 0 1 1
1 43 4 2 7.24 1.6 1.8 131 1.1 0 0 0 1 2
1 60 26 4 7.5 1.3 2.7 104 1.1 0 0 0 2 2
1 80 15 1 7.32 1.6 1.8 107 1.3 0 0 0 1 1
1 90 14 1 7.36 1.1 1.8 124 2.1 0 0 0 1 2
0 120 10 4 7.41 1 2 145 1.4 0 0 0 0 0
0 70 8 7 7.38 1.9 1.6 134 1.2 0 0 0 1 1
0 87 8 5 7.32 1.6 3.1 126 0.8 0 0 0 1 1
1 73 2 7 7.45 1 1.4 313 0.9 0 0 0 1 2
1 78 21 11 7.31 2.1 8.6 131 0.6 1 4 3 1 1
1 86 8 6 7.32 2.2 2.2 113 1 0 0 0 1 1
1 83 10 10 7.49 1.1 1.3 104 1.3 0 0 0 2 1
1 63 2 11 7.28 2.2 1.5 108 1.6 0 0 0 1 1
1 53 3 8 7.23 4.2 2.3 161 0.6 1 4 6 2 1
1 64 2 6 7.35 1.3 2.4 131 1.6 0 0 0 2 1
1 70 10 7 7.29 1.9 2.6 138 1.3 0 0 0 1 1
1 83 11 6 7.3 1.9 1.7 132 2.2 0 0 0 1 1
0 86 8 8 7.31 3.8 1.5 294 1.6 0 0 0 1 1
1 88 7 8 7.33 1.6 1.4 108 2.1 0 0 0 1 1
1 73 11 6 7.32 1.9 2.3 141 2.4 0 0 0 2 1
1 77 11 7 7.21 2.1 1.5 121 2.6 0 0 0 2 1
1 60 11 5 7.34 2.9 1.9 133 1.6 0 0 0 1 1
1 57 0 9 7.14 3.4 2.9 104 1.3 0 0 0 1 1
1 73 3 6 7.3 1.2 1.6 134 2.1 0 0 0 1 1
0 70 0 12 7.3 3.2 3.4 129 1.3 0 0 0 0 0
1 70 4 9 7.21 1.6 1.5 216 1.8 0 0 0 1 1
1 73 2 7 7.35 2.1 1.4 169 1.4 0 0 0 1 1
1 70 8 3 7.22 1.8 1.4 92 1.9 0 0 0 1 1
1 70 8 10 7.3 1.7 3.5 72 1.3 0 0 0 1 1
1 75 7 3 7.25 2.9 1.7 184 1.3 0 0 0 2 1
1 76 3 6 7.23 2 1.6 138 1.3 0 0 0 1 1
1 57 2 13 7.09 8.6 1.8 189 1.9 0 0 0 1 1
1 63 13 6 7.36 2.1 1.1 138 1.7 0 0 0 1 1
1 69 6 10 7.21 4.1 1.5 192 1.2 0 0 0 1 1
1 70 13 11 6.96 10 2.6 199 1.1 0 0 0 1 1
1 69 6 7 7.11 3.3 1.5 186 1.2 0 0 0 4 1
1 40 3 17 7.08 12 1.2 194 0.7 0 0 0 1 1
1 53 5 10 7.23 4.8 3.6 216 1.6 1 4 1 1 1
1 67 5 15 7.19 2.1 2.9 211 0.9 0 0 0 1 1
1 40 5 8 7.01 11 2.9 305 0.8 1 4 1 1 1
1 67 7 4 7.23 5.7 2.7 210 1.4 1 4 5 3 1
1 50 9 10 7.21 5 4 111 0.3 1 5 2 2 1
1 53 11 14 6.9 11 2.4 228 1 0 0 0 1 1
1 77 6 6 7.23 3.8 1.4 134 0.8 0 0 0 1 2
1 63 6 15 7.23 2.9 1.8 136 0.2 0 0 0 1 1
1 60 6 12 7.25 3.2 1.6 225 1.3 1 4 3 1 2
1 55 2 10 7.18 4.5 1.5 202 1.8 0 0 0 1 2
1 53 4 10 7.26 3.2 1.8 167 0.6 0 0 0 1 1
1 60 5 8 7.18 4.3 2.6 206 0.3 1 4 3 1 2
1 65 12 10 7.21 4.9 1.7 212 0.8 0 0 0 1 1
1 60 10 9 7.19 6 1.9 231 0.7 0 0 0 1 1
1 53 6 14 7.11 4.3 2.1 186 0.3 0 0 0 1 2
1 67 11 10 7.18 6 1.8 307 2.2 0 0 0 1 1
1 82 3 10 7.23 4.1 4.2 191 0.9 1 4 3 1 1
1 47 15 12 7.13 3 3.1 218 0.4 1 4 4 2 1
1 0 2 11 7.22 3.5 2.3 74 0.7 0 0 0 1 1
1 102 0 8 7.3 1.7 1.4 163 0.6 0 0 0 1 1
1 47 12 11 7.14 7.6 1.9 151 0.6 0 0 0 1 1
1 55 7 16 7.05 7.9 1.8 160 0.3 1 5 1 1 1
1 70 2 10 7.26 2.2 2.5 222 0.5 0 0 0 0 0
1 67 4 13 7.16 5.4 1.7 83 0.3 0 0 0 0 0
1 50 4 10 7.16 4.9 2.9 294 0.7 0 0 0 1 2
1 87 7 7 7.15 2.3 1.4 190 1.4 0 0 0 1 1
1 57 13 11 7 6.3 3.6 279 0.3 1 4 10 1 1
1 47 15 8 7.26 3 3.5 220 0.5 0 0 0 2 1
1 63 3 12 7.08 12 2.2 283 0.4 0 0 0 2 1
1 50 11 9 7.2 3 2.3 206 1.1 0 0 0 1 1
1 37 3 15 7.14 4.1 7.7 171 0.2 1 4 2 1 1
1 50 1 15 7.14 3.9 4.1 212 0.5 0 0 0 1 1
1 53 0 11 7.17 6.9 2.7 108 0.7 0 0 0 2 1
1 53 12 7 7.21 4.3 4.8 110 0.3 1 4 4 2 1
1 73 1 12 7.21 3.3 2.2 209 0.1 0 0 0 1 1
1 61 2 8 7.25 3.9 1.6 188 0.8 0 0 0 1 1
1 63 6 8 7.21 4.3 2.2 128 1.2 0 0 0 1 1
1 82 11 7 7.25 3.8 2.2 183 0.4 1 4 8 1 1
1 47 15 8 6.94 12 1.9 236 0.8 0 0 0 1 1
1 63 11 6 7.21 4.1 2 191 1.1 0 0 0 2 1
1 49 3 9 7.16 12 2 173 0.2 0 0 0 1 1
1 73 9 10 7.31 2.1 1.3 104 1.6 0 0 0 1 1
